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Pierce's Disease (PD) is one of the most devastating diseases threatening grapevines 
in the USA caused by the Gram negative bacterium Xylella fastidiosa. There is no 
effective control method for Pierce’s Disease and control is mainly achieved by 
suppressing transmission of the glassy winged sharpshooter (GWSS) insect vector. 
The study of the surface proteins of X. fastidiosa may provide targets that may be 
attractive sites for intervention. MopB is an outer membrane protein, which has been 
identified on the X. fastidiosa surface. Blocking MopB with antibodies may prevent 
or reduce transmission of the pathogen. 
 
The main goal of this research was to generate recombinant antibodies to be used to 
investigate the interaction of MopB with the plant and GWSS. Towards this goal, 
recombinant MopB has been produced and used with sera from five mice immunized 
with whole heat killed X. fastidiosa in an Enzyme-Linked Immunosorbent assay 
(ELISA). The ELISA results revealed the presence of antibodies against the 
recombinant MopB protein. In vitro combinatorial antibody ribosome display 
libraries were assembled from immunoglobulin transcripts rescued from the spleens 
of mice immunized with heat-killed X. fastidiosa. The libraries were used in a single 
round of selection against the outer-membrane protein MopB, resulting in the 
isolation of a panel of recombinant antibodies. The potential use of selected anti-
MopB antibodies was demonstrated by the successful application of the 4XfMopB3 
antibody in ELISA, Western blot and immunofluorescence assays.  
 
Pantoea agglomerans, a candidate bacterium for PD paratransgenic approach was 
engineered to express and secrete selected anti-MopB (4XfMopB3) single chain 
antibody. The expression cassette that include the pelB secretion signal was created 
and tested for its efficiency	   in secreting the 4XfMopB3 antibody in E. coli and  
P. agglomerans. The 4XfMopB3 antibody was successfully expressed and secreted in  
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Chapter 1: Introduction 
 
1.1  Pierce’s Disease Background 
 
One of the most devastating agricultural and economically important diseases 
threatening grapevines  (Vitis vinifera)  in the USA is Pierce’s Disease (PD). This 
disease occurs mainly the parts of America, which have mild winters (Purcell et al., 
1979). The prevalence of this particular disease decreases in regions with colder 
temperatures (i.e. places in higher altitudes and/or further away from coastal regions). 
However, the most affected regions in America occupy the stretch from Florida to 
California.  
 
In 1882 the plant pathologist Newton B. Pierce studied the first outbreak of the 
disease known as “Anaheim grapevine” or “grape mystery” disease in the Santa Ana 
River Valley near Anaheim in Southern California. Pierce reported the disease in 
1891 without identifying the cause of the disease. This disease is now known as 
Pierce’s disease of grape. 
 
During 1939 -1945 PD was identified as a vector-borne disease.  Xylem sap-sucking 
insects such as sharpshooters (subfamily Cicadellinae in the leafhopper family 
Cicadellidae) and spittlebugs (family Cercopidae) were discovered as vectors of the 
PD pathogen (Morano et al., 2008, Ramirez et al., 2008, Myers et al., 2007). These 
insects play an important role in spreading the pathogen from plant to plant.  
 
Initially, PD was considered to be a viral disease (Hewitt et al., 1946) until the 
disease was suppressed by chemotherapy (tetracycline antibiotic) and thermotherapy 
in 1971, which indicated that PD might not be a viral disease. Furthermore a 
“rickettsia-like” bacterium was identified in the infected grapevine xylem vessels by 
the use of electron microscopy (Hopkins and Mortense, 1971, Hopkins and Mollenha, 
1973, Goheen et al., 1973). In 1987, the causative agent of PD was grown in culture 





1.2  Xylella fastidiosa Bacterium 
 
Xylella fastidiosa is a rod-shaped Gram negative xylem limited fastidious 
phytopathogen bacterium with dimensions of 0.25 to 0.35 µm in radius and 0.9 to  
3.5 µm in length (De la Fuente et al., 2007). It is non-flagellate, non-sporulating, has 
distinctive rippled cell walls, two types of pili (Type I and Type IV) and a twitching 
motility (Li et al., 2007, Nyland et al., 1973).  
 
X. fastidiosa is a nutritionally fastidious aerobic bacterium that can survive in high 
turbulence, low nutrients, and can withstand host defense responses of plants and 
insects (O'Toole et al., 1999). This bacterium resides in plant xylem environment 
which contains dilute solutions of essential nutrient sources such as specific amino 
acids, mainly glutamine and asparagine, organic acids and inorganic ions.  
X. fastidiosa has specialised mechanisms to concentrate and absorb the essential 
nutrients in such environments (Purcell and Hopkins, 1996). These nutrient sources 
are necessary for the bacterium to produce energy and grow. Thus, understanding the 
carbohydrate metabolism of X. fastidiosa provides important information about the 
plant-pathogen interactions. 
 
X. fastidiosa has more than 100 host plant species (Hopkins and Purcell, 2002). 
Strains of X. fastidiosa are involved in several important economically important crop 
diseases such as PD in grape (Davis et al., 1978), citrus variegated chlorosis (CVC) 
(Chang et al., 1993), almond leaf scorch (ALS) (Mircetich et al., 1976), alfalfa dwarf 
(Goheen et al., 1973), phony peach, plum scald (Wells et al., 1981), several species 
of ornamental plants, e.g. oleander leaf scorch (OLS) (Purcell et al., 1999) and 
bacterial leaf scorch (BLS) of Ulmus spp., Quercus spp. (Hearon et al., 1980), Acer 
spp. (Sherald et al., 1987), and Platanus spp. (Sherald et al., 1982). This bacterium 
has also been detected asymptomatically in many plant species such as wild grasses, 
sedges, lilies, and various bushes and trees (Raju et al., 1983, Hopkins and Adlerz, 




1.2.1  Xylella fastidiosa Genome Sequence 	  
X. fastidiosa is the first non-viral plant pathogen to have its genome (2Mb) 
completely sequenced (Van Sluys et al., 2003, Simpson et al., 2000). Comparative 
genome analysis has provided valuable information of genes, metabolic pathways and 
potential virulence factors that may be involved in pathogenicity (Simpson et al., 
2000).  
 
Based on X. fastidiosa genomic sequence analysis potential virulence factors are 
known as pili, exoploysaccharides, biofilm formation and cell aggregation, 
degradative enzymes and systematic movement from vessel to vessel that may be 
involved in pathogenicity (Simpson et al., 2000). In addition the open reading frames 
(ORF) encoding a polygalacturonase (PG), three endo-1-4β-glucanases, a 
cellobiohydrolase, three endo-β-xylanases and twoβ-xylosidases have been 
identified. These enzymes, especially PG, may have an important role in 
pathogenicity via digesting the pit membrane, the degraded primary cell walls and 
middle lamella of vessels that acts as porous filters allowing free passage of the water 
and nutrients while limiting passage of large objects such pathogens (Van Sluys et 
al., 2003, Perez-Donoso et al., 2010, Roper et al., 2007). The carbohyrate metabolism 
of X. fastidiosa has also been studied and suggests that this pathogen can only use a 
few sugars or sugar polymers such as glucose, fructose, mannose, ribose,  
N-acetylglucosamine, cellulose and glycerol (Almeida et al., 2004, Chang and 
Donaldson, 2000, Chatterjee et al., 2008). 
 
1.2.2  Pathology  
 
The precise mechanism by which X. fastidiosa causes disease is not clearly 
understood however the ability of the pathogen to colonize both the xylem of the 
grape vine and in the foregut of the GWSS vector is well established (Almeida et al., 
2004). 
 
Bacterial biofilm formation plays an important role for X. fastidiosa to survive and 
replicate in both plant and insect with low nutrient environments (Voegel et al., 2010, 
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Guilhabert and Kirkpatrick, 2005, de Souza et al., 2003, Rodrigues et al., 2008). The 
attachment of the bacterium to the host surface is the first step of biofilm formation. 
On the X. fastidiosa surface there are fimbrial and afimbrial adhesins which are 
involved in bacterium attachment (Li et al., 2007).  
 
Two classes of fimbriae have been identified for X. fastidiosa, type IV encoded by pil 
genes and type I encoded by the fim operon (Meng et al., 2005). The type I pili are 
responsible for the bacterium-bacterium adhesion, aggregation and biofilm formation 
by an exopolysaccharide (EPS) secretion, while type IV polar pili are responsible for 
twitching motility (Simpson et al., 2000, de La Fuente et al., 2007, Li et al., 2007). 
The afimbrial adhesins such as haemagglutinin adhesins (HAs) are involved in 
bacterial attachment to the plant host cells (Voegel et al., 2010). 
 
1.3  Pierce’s Disease Life Cycle 
 
After an epidemic of PD in Northern California (1939 to 1945), xylem sap-sucking 
insects such as sharpshooter (subfamily Cicadellinae in the leafhopper family 
Cicadellidae) and spittlebugs (family Cercopidae) were discovered as vectors of PD 
pathogen (Morano et al., 2008, Ramirez et al., 2008, Myers et al., 2007). In 1989 a 
new shapshooter, Homalodisca vitripennis, also known Glassy-winged sharpshooter 
(GWSS) was introduced to California from Florida (Blua et al., 1999).  
 
X. fastidiosa is transmitted between plants by xylem sap-sucking insects. While these 
insects are feeding from the infected plants, they rapidly (less than 2 hours) pick up 
the bacterium (Backus et al., 2009, Morano et al., 2008, Ramirez et al., 2008, Myers 
et al., 2007, Backus and Morgan, 2011). X. fastidiosa attaches itself to the buccal 
cavity in the foregut of the insect (Hill and Purcell, 1995) and while infected insects 
are feeding again using their sucking mouthparts to access the xylem sap via the 
water conducting xylem vessels the bacteria can immediately transfer to the plant 
(Purcell et al., 1979, Nadarasah and Stavrinides, 2011, Myers et al., 2007, Ramirez et 
al., 2008, Jackson et al., 2008). 
 
The bacterium is directly injected into the xylem vessels through the insect food canal 
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(Wayadande et al., 2005, Myers et al., 2007, Ramirez et al., 2008, Jackson et al., 
2008, Nadarasah and Stavrinides, 2011). The xylem sap can pass through the 
bordered pits (channels that connect vessels to each other), but due to the presence of 
pit membrane, the degraded primary cell walls and middle lamella of vessels that acts 
as porous filters allowing free passage of the water and nutrients while limiting 
passage of large objects such pathogens, X. fastidiosa is blocked (Baccari and 
Lindow, 2011, Choat et al., 2003, Chatterjee et al., 2008). 
 
From the site of inoculation X. fastidiosa attaches to the xylem walls, multiplies and 
spreads to colonize the xylem, forming biofilm-like colonies, which can clog the 
xylem vessels and block water transport network, causing scorch like symptoms. The 
colonization process requires X. fastidiosa to move within the xylem. The bacterium 
must pass through the pit membrane, which acts as porous filters, in order to move 
from one vessel to another (Stevenson et al., 2004). However, X. fastidiosa can not 
use the water flow to pass from one vessel to another via the pit membrane due to the 
size of the bacterium. Thus, movement of the bacterium is an active process 
dependent on the pathogens ability to disrupt the pit membrane (Figure 1.1). For 
intervessel migration and spread through the plant, the pathogen needs to digest 
pectin in the pit membrane, which also provides a nutrient source supplementing the 
low amount of nutrients in the xylem sap and also leads to the exposure of additional 
cell wall polysaccharides that could be digested by other extercellular enzymes such 
as glucanases and xylanases (Chatterjee et al., 2008). 
 
The blockage of the xylem is related to the large cell aggregation of the pathogen in 
the xylem and not the number of vessels that are colonized. The bacterium spread in 
the xylem is limited due to the pit membrane and possibly because of the tyloses and 
polysaccaride-rich gels plants produce to block the xylem in response to infection 
(Chatterjee et al., 2008, Cheng et al., 2009, Perez-Donoso et al., 2007, Hopkins, 




              
 
Figure 1.1 X. fastidiosa is delivered directly into the xylem vessels by xylem sap-feeding insect 
vector. X. fastidiosa is xylem-limited and can only spread to the neighboring xylem vessel by 
disrupting the pit membrane (PM). Picture is adapted from (Chatterjee et al., 2008). 
 
1.4  Pierce’s Disease Symptoms 
 
Usually PD symptoms are not noticed until the time of fruit maturation, or in late fall 
when the host plant is senescing (Hopkins, 1989). 
 
The initial symptom of the infection is delayed growth in the spring, leaf chlorosis 
(yellowing) and sudden drying or scorching of the margin of the leaf. These 
symptoms are followed by loss of the affected leaves while the petioles still remain 
on the canes, brown and green patches appear on the vine. In the late stage of the 
infection, wilting of the fruit and drying up will occur and the infected plant produces 
stunted, chlorotic shoots. The grape plants stop growing and the plant dies within a 
year or over a few years (Stevenson et al., 2005, Morano et al., 2008, Hopkins, 
2005).  
 
1.5  Detection Methods for Xylella fastidiosa  	  
Currently detection methods for X. fastidiosa are based on light microscopic and 
electron microscopic (French et al., 1977) visualization of the bacterium in vessels in 
cross-sections of petioles or isolating the bacteria using suitable selective media (Raju 
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et al., 1982, Wells et al., 1983, Davis et al., 1983) followed by biochemical and 
serological analysis. Microscopic detection is slow and inefficient. Another method 
to detect X. fastidiosa is culturing methods, which in comparison with other methods 
such as serology, is very slow. To detect and identify Xylella bacterium, serological 
methods (ELISA or fluorescent antibodies) are easier than culturing and microscopic 
methods, but less sensitive (French et al., 1978, Hopkins and Adlerz, 1988, Sherald 
and Lei, 1991). ELISA reliably detects only 105 or greater cells isolated per gram 
plant tissue due to its low sensitivity, thus low number of cells are not detectable. In 
addition, different strains show different quantitative reaction to anti-sera and false 
positive results may occur due to unidentified plant components, which can interfere 
with the assay (Carbajal et al., 2004). Recently, for X. fastidiosa detection, specific 
DNA hybridization probes and polymerase chain reaction (PCR) primers have been 
developed (Minsavage et al., 1994, Oliveira et al., 2002). Moreover, by the use of 
such specific and sensitive methods, low numbers of X. fastidiosa in its insect vectors 
are detectable (Yonce and Chang, 1987). A high throughput DNA isolation method 
also has recently been developed to detect X. fastidiosa in both plant and insect 
tissues (Brady et al., 2011). 
 
Other methods such as grafting to susceptible indicator plants or vector tests 
(Hutchins et al., 1953), SDS-PAGE (Bazzi et al., 1994), dot immunobinding assay 
(DIBA) and Western blot (Chang et al., 1993, Hill and Purcell, 1995) are still 
routinely used to detect X. fastidiosa (Oliveira et al., 2002).  
 
1.6  Management of Pierce’s Disease  
 
There is no efficient control for PD at the present. It is difficult to control this disease 
due to several factors: 1) no efficient methods for controlling infected plants, 2) 
sharpshooter vectors are extremely mobile and have a large host-plant range that 
includes many common ornamental and crop plants and 3) X. fastidiosa is capable of 
infecting a wide range of plant hosts without causing symptoms. Furthermore, new 
strains of X. fastidiosa may be spread via the international movement of plants and 
animal materials (Blua et al., 1999). 
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To prevent PD, a single quick efficient solution is required but, until now, several 
different strategies have been attempted to control the disease. In 1989, Van Emden 
suggested that protection against plant diseases could be classified as cultural, 
chemical, biological or strain improvement.  
 
Culture Method  
Vines infected with X. fastidiosa that show PD symptoms should be removed 
completely or isolated because they act as sources of inoculum for infection of 
other plants (Gubler et al., 2006). This strategy does not decrease the subsequent 
rate of increase of PD (Hopkins and Purcell, 2002). 
 
Chemical control  
- Chemical control can be used to reduce the insect vector (sharpshooters) 
populations using xylem-translocated insecticide such as the neonicotinoid, 
imidacloprid (Purcell et al., 1999, Krewer et al., 2002). Vector control efforts have 
not succeeded in California or in Florida (Hopkins and Purcell, 2002). 	  
- Plant disease control (antibiotics and antimicrobials): antibiotics such as 
tetracycline and penicillin, which are effective in inhibiting the bacterium; and 
micronutrients such as zinc, manganese and copper that are toxic to the bacterium 
can be utilised to avoid a potential proliferation of the pathogen and hence 
transmission of the disease from the infected plants to a healthy recipient. In fact, 
the use of chemicals is classified as the second stage response. Unfortunately, 
chemicals do not offer a long term solution to PD (Hopkins and Purcell, 2002). 
 
Biocontrol 
Traditional biological control of PD relies on a natural enemy or a pathogen that 
attacks a particular pest. However, one should discover the natural habitat of the 
competing organism in question (Torchin et al., 2003).  
 
- Parasitoid wasps: several mymarid and trichogrammatid species such as 
Gonatocerus ashmeadi Girault, G. triguttatus Girault, G. morrilli Howard, G. 
fasciatus Girault, and most recently a strain of Anagrus epos from Minnesota have 
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been identified as the most common natural enemies of the GWSS eggs 
(Triapitsyn and Phillips 2000, Pilkington et al., 2005, Krugner et al. 2008).  
 
-  Entomopathogenic fungi: Pseudogibellula formicarum, Metarhizium anisopliae 
and Hirsutella homalodiscae nom. prov., are the two possible entomopathogenic 
fungi species that can be used for PD biocontrol (Kanga et al. 2004, Boucias et al. 
2007). Hirsutella homalodiscae nom. prov., was determined to be the most 




Using plants bred for resistance to X. fastidiosa (Hopkins and Purcell, 2002), is the 
only efficient control mechanism for PD in Southeastern United States and parts of 
California. To maintain the productive lifespan of grapes in these regions it is 
necessary to replace the existing grapevines with varieties resistant to the pathogen 
(Mortensen et al., 1977, Hopkins and Purcell, 2002). 
 
Investigations revealed that PD kills almost all European types of grapes  
(V. vinifera), American type (V. labrusca) and French-American hybrid grapes. 
However the native species to the southeastern United States such as muscadine 
grapes (V. rotundifolia) and V. vinifera were found to be resistant or tolerant to PD 
(Raju and Goheen, 1981, Hopkins and Purcell, 2002). 
 
A rethink of approaches and novel solutions are urgently required. One such 
approach is to attack X. fastidiosa in the insect vector. This can be achieved by using 
resident symbiotic organisms that reside in the same vicinity as X. fastidiosa in the 
insect. Manipulation of resident microorganisms to express and secrete an anti-
Xylella factor, and then be re-introduced into the GWSS is an example of 
paratransgenic (PTG) control (Ramirez et al., 2008). In this way the transmission of 
the pathogen from the insect vector into the plant xylem region may be prevented 
(Miller, 2007).  
 
According to the College of Natural Resources, University of California, Berkeley 
there are more than 145 strains of X. fastidiosa that cause PD. Future disease 
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management may be based on the complete genome sequence of X. fastidiosa. A few 
X. fastidiosa strains are completely sequenced and annotated. These genomes 
revealed pathogenicity factors for this bacterium such as toxins, antibiotics, and iron 
sequestration systems (Hopkins and Purcell, 2002). 
 
1.7  Pierce’s Disease Paratransgenesis Approach (PTG) 	  
1.7.1  Paratransgenesis Approach 	  
Dr. Frank Richards and his colleagues introduced a novel mechanism, symbiotic 
control, for eradicating pest-borne diseases. He established the advanced stage of 
genetic transformation of a gut symbiont bacterial Rhodococcus rhodnii, with a 
plasmid to express a foreign gene in Rhodnius prolixus the Chagas disease vector 
(Beard et al., 1992, Durvasula et al., 1997, Miller, 2011). Indeed, symbiotic control 
does not primarily target the insect vector, which is normally-directly linked to the 
associated disease. Rather, symbiotic control targets the pathogen, the causative agent 
of the disease by genetic manipulation of a vector’s naturally occurring 
microorganisms such as bacteria, viruses or fungi to compromise competence to 
transmit a particular agent (Miller, 2011, Ramirez et al., 2008). The pathogen’s 
ability to survive is therefore, undermined. An indirect way to put the pathogen’s 
survival in jeopardy is to actually prevent its transmission from the insect vector into 
the host (Miller, 2007, Coutinho-Abreu et al., 2010). Figure 1.2 shows an illustration 
of paratransgenesis using a bacterial symbiont. 
 
Currently, paratransgenic approaches are being investigated for many agricultural 
pests and diseases. Paratransgenesis is used to interfere with triatomid bug 
transmission of the Chagas disease pathogen (Beard et al., 2001, Ben Beard et al., 
2002, Fieck et al., 2010, Matthews et al., 2011), to interfere the HIV attachment to its 
target cells (Chang et al., 2003, Rao et al., 2005), and to eliminate Candida infections 
from biofilms in chronically infected patients (Beninati et al., 2000). Paratransgenesis 
also has been used for malaria (Ren et al., 2008, Bisi and Lampe, 2011), to reveal 
colitis by cytokines delivery to mammalian guts (Steidler et al., 2000, Steidler, 2001), 





Figure 1.2 Paratransgenesis. An illustration of insect transformation using the transgenic symbiont 
procedure is presented. 1) Bacterial symbionts can be genetically modified to express a gene blocking 
pathogen development in vectors; 2) Symbiotic bacteria are transformed with plasmids expressing a 
gene (red) to inhibit the pathogen development in the insect gut; 3) The transformed symbionts are 
acquired by insect hosts though larvae or nymph feeding; 4) Once an insect acquires the transformed 
symbionts, these microorganisms can express proteins to inhibit the pathogen development. Picture is 
adapted from (Coutinho-Abreu et al., 2010). 
 
 
1.7.2  Pierce’s Disease Paratransgenesis  	  
In order to apply a PTG approach for PD, several components are required: 1) 
symbionts of the GWSS need to be identified and cultured in vitro, 2) methods for 
transforming symbionts need to be developed, 3) methods for reintroducing the 
symbionts into the GWSS devised, 4) strategies for retaining and spreading the 
paratransgenic bacteria investigated and finally 5) specific anti-X. fastidiosa effector 
molecules developed.  
 
Bextine et al., (2004) and Lacaval et al., (2009) identified probable bacterial 
candidates for PTG approaches for PD, which are Alcaligenes sp., Chryseornonas 
sp., Ralstonia sp. from the GWSS and additionally Pantoea agglomerans, C. 
flaccumfaciens and Methvlohacterium spp. (Lacaval et al., 2009). All of the 
suggested candidates can be cultured and the transmission mode of these endophytes 
is similar to the transmission of X. fastidiosa. In 2005, Bextine et al., reported that 
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Alcaligenes xylosoxidans (Axd) shows suitable properties as a delivery vehicle for 
anti-Xylella strategies (Bextine et al., 2005).  
 
In 2004, a genetically modified Axd containing a DsRed fluorescent marker gene 
(DsAxd) was introduced to GWSS. These modified Axd were able to occupy the 
same region in the foregut of the insect that the pathogen occupies and colonize the 
cibarial region of the insect (Bextine et al., 2004). The presence of DsRed was traced 
in different plants such as lemon (Citrus limon), orange (Citrus sinensis ‘‘sweet 
orange’’), grapevine (Vitis vinifera cv. Chardonnay), periwinkle (Vinca rosea), crepe 
myrtle (Lagerstroemia indica) and chrysanthemum (Chrysanthemum grandiflora cv. 
‘‘White Diamond’’) as a direct result of Axd transmission by GWSS. Many reports 
suggested that the DsAxd can also be introduced into the grapevines but as the 
GWSS samples were originally obtained from citrus groves in the Agricultural 
Operations plot at the University California Riverside it seems that they are more 
adapted to citrus than to grapevine (Miller, 2007, Bextine et al., 2005). 
 
1.8  Anti-Xylella Proteins 
 
According to X. fastidiosa genome sequencing analysis it is possible to predict and 
explore the surface exposed components that may potentially play a role in bacterial 
virulence and or be involved in attachment or biofilm formation in either the plant or 
insect. If identified, such molecules may be used as targets to further understanding 
and ultimately develop strategies to inhibit and/or prevent PD by disrupting 
colonization in either the GWSS or the plant. Moreover plentiful surface displayed 
proteins also provide targets for agglutination of the pathogen independent of the role 
in virulence, providing a generic alternative mode of transmission disruption.  
 
To develop anti-Xylella proteins, it should be considered that these proteins should 
be: (1) specific for the target organism and (2) if possible prevent some pathogenicity 
characteristic, for example to inhibit the ability of attaching to the insect bucal cavity 
or to the plant xylem.  There are several anti-Xylella antimicrobial peptide candidates. 
Kuzina et al., (2006) reported that antibiotics and antimicrobial peptides show 
activity against X. fastidiosa, which may protect the plants from developing PD. 
However antimicrobial peptides show less specificity. The production of single chain 
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antibodies (scFv’s) is a potential avenue for anti-Xylella factor generation. Lampe et 
al., (2007) attempted to screen single chain antibodies (scFvs) against the outer 
protein coat of X. fastidiosa from a phage antibody library (Miller, 2007, Lampe et 
al., 2006). 
 
Recently the expression of X. fastidiosa fimbrial and afimbrial proteins has been 
investigated during biofilm formation. These proteins showed different distribution 
pattern during biofilm formation in the xylem vessels (Caserta et al., 2010). 
Furthermore, haemagglutinin adhesin, an outer membrane protein, has been localized 
and characterized in X. fastidiosa (Voegel et al., 2010). Developing scFv antibodies 
against the candidate surface protein targets on X. fastidiosa may be a key to inhibit 
bacterial attachment and to prevent PD. 
 
1.9  Xylella fastidiosa Outer Membrane Protein MopB  
 
The study of the surface proteins of X. fastidiosa may provide molecules that attach 
either in the plant or insect, and which may be attractive targets for intervention. 
According to previous studies, and sequence analysis of outer membrane proteins, 
MopB has been identified on the surface of X. fastidiosa. This protein belongs to the 
OmpA family and is partially exposed on the surface of the bacterium (Bruening, 
2002, Bruening, 2003, Bruening, 2004, Fjellbirkeland et al., 2000). MopB is 
identified as an important target for disruption of the X. fastidiosa cell or interference 
with the X. fastidiosa infection cycle because 1) MopB is the most abundant protein 
in membrane preparations, 2) the MopB sequence was identical in all X. fastidiosa 
subspecies and 3) MopB is accessible on the X. fastidiosa surface (Dandekar et al., 
2012, Bruening, 2004). Blocking MopB with antibodies may prevent the initial 
attachment of bacteria to the xylem or the buccal cavity of the GWSS. 
 
Although the X. fastidiosa MopB gene has been identified, the production of high 
levels of the encoded protein has not previously been reported. Membrane proteins 
are notoriously difficult to express at high levels in Escherichia coli (E. coli) 
(Bruening, 2003, Bruening, 2005).  
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To develop an anti-MopB antibody first, a leaderless X. fastidiosa MopB gene should 
be engineered, to retain the expressed MopB protein in the E. coli cytoplasm. Then 
the recombinant MopB protein should be characterized using mice sera previously 
immunized with heat-killed X. fastidiosa and used as a selection bait to pull out 
recombinant single chain antibodies from an in vitro ribosome antibody display 
library (Mattheakis et al., 1994, Hanes and Pluckthun, 1997, He and Taussig, 1997) 
assembled from immunoglobulin genes rescued from the same X. fastidiosa immune 
mouse spleens.  
 
1.10  In vitro Ribosome Display 
 
Display technology is used to isolate the DNA or RNA encoding protein sequence. In 
this technology not only the genetic information is recovered but also functional 
protein is developed. Based on this technology there are numerous methods 
developed and validated. These methods could be divided into two categories: (1) cell 
based methods such as phage display (Winter et al., 1994) and surface display 
(Georgiou et al., 1997, Shusta et al., 1999) as well as (2) cell-free methods such as 
ribosome display (Mattheakis et al., 1994, Hanes and Pluckthun, 1997, He and 
Taussig, 1997) and mRNA display (Roberts and Szostak, 1997).  
 
Ribosome display technology is a fully in vitro, cell-free method, which overcomes 
many limitations of cell-based methods by producing in vitro protein-mRNA 
complexes. The advantages of ribosome display comparing to cell-based methods are 
efficient screening of large libraries without compromise of the library size by 
transformation efficiency, selecting high affinity combining sites, and eukaryotic cell- 
free systems are capable of post-translational modifications. Furthermore, as no cell 
culture is involved it is quick and efficient (He and Taussig, 2007). The only 
limitation in ribosome display is the accessible functional ribosome in the reaction for 
the library, which depends on the library size. 
 
This technology is based on in vitro protein evolution to produce proteins, which are 
able to bind to the desired ligand by using the principal of coupling individual 
proteins (phenotype) to their corresponding mRNA (genotype) to produce stable 
protein-ribosome-mRNA (PRM) complexes (Figure 1.3). The stable protein 
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(antibody)-ribosome-mRNA (ARM) complexes are the association of individual 
antibody fragments with their related mRNA (He and Taussig, 2002).  
 
The PRM complexes formation is achieved via deletion of the stop codon from the 
mRNA, which causes stalling of the translating ribosome at the end of mRNA. The 
linkage of protein-mRNA allows simultaneous isolation of the desirable proteins 
(antibodies) through affinity for an immobilized ligand. The protein-mRNA complex, 
which binds tightly to the ligand will first be reverse transcribed to cDNA and then 
PCR amplified to recover the DNA encoding protein sequence (He et al., 2004). 
 
In vitro ribosome display can be used to select functional single chain antibodies 
(scFv’s) against recombinant X. fastidiosa surface protein MopB using constructed 











Figure 1.3 Principle of in vitro ribosome display. (a) Library construction.  DNA library is amplified 
using PCR and is transcribed to RNA by T7 RNA polymerase. Ribosome binds to the ribosome-
binding site (RBS) and translates RNA into a polypeptide. Due to the absence of a stop signal codon 
the mRNA, protein, the spacer peptide and the ribosome remains bound. (b) Selection cycle. DNA 
library is first amplified by PCR, as a T7 promoter, ribosome binding site, the gene, the spacer and no 
stop codon. The amplified DNA library is used in an in vitro coupled transcription/translation to form 
mRNA, the related protein and the ribosome complex (PRM complex). The PRM complexes are 
affinity selected from the transcription/translation mixture by binding of the immobilized antigen. The 
bound PRM complexes can then be dissociated and the RNA is isolated from the selected PRM 
complexes. Isolated mRNA is reverse transcribed to cDNA, and cDNA is then amplified by PCR or 
One-step RT-PCR to recover the DNA encoding protein sequence. Picture is adapted from (Yan and 
Xu, 2006). 
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1. 11  Protein Expression in Escherichia coli 
 
1.11.1  Recombinant Protein Expression 
 
A wide range of expression systems (cell-based and cell-free systems) have been 
developed for recombinant protein expression (e.g. antibody). Cell-based systems are 
the most commonly used expression systems in which the foreign DNA is introduced 
to the host cell (bacteria (Baneyx, 1999), yeast (Cregg et al., 2000), Baculovirus 
(Kost et al., 2005) and mammalian cells (Rosser et al., 2005)) by an expression 
vector.  
 
One routinely used bacterial expression system is based on Escherichia coli (E. coli), 
mainly used for recombinant protein expression due to its well studied genetics, 
simplicity, fast growth, easy cultivation, low cost, the availability of compatible tools, 
available varieties of plasmids and bacterial hosts including mutant strains (Sorensen 
and Mortensen, 2005). However, soluble proteins expression in E. coli is still 
restricted and a couple of empirical rules have been developed to guide the design 
and selection of an expression system (Makrides, 1996).  
 
To design a recombinant expression system, a plasmid with a compatible genetic 
background and essential genetic elements (origin of replication (ori), antibiotic 
resistance marker, transcriptional promoter, translation initiation regions (TIRs) and 
transcriptional and translational terminators) are required.  
 
A strong transcriptional promoter will lead to high level of gene expression. The 
protein synthesis should be controlled via the presence of the repressor to exhibit a 
minimal level of basal transcription controlled by a suitable suppressor. In most cases 
the Lac repressor, encoded by lacI gene or its mutants are used as the suppressor. 
Promoters are normally induced thermally or chemically. One of the most commonly 
inducers is isopropyl β-D-1-thiogalactopyranoside (IPTG) (Hannig and Makrides, 
1998).  
 
Bacterial strains and their genetic backgrounds are also important for protein 
expression. For an expression strain, several key features such as deficiency in the 
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most harmful proteases, maintenance of expression plasmid stability and the genetic 
elements relevant to the expression system (e.g., DE3) (Sorensen and Mortensen, 
2005) have been identified. One of the most widely used strains for high-level 
recombinant protein expression is E. coli BL21. This strain is derived from E. coli B, 
a T7 RNA polymerase-based expression systems with a lysogenic host (λDE3) 
encoding T7 RNA polymerase gene, under the control of lacUV5 promoter. 
Moreover this strain carries two proteases deficiencies, OmpT and Lon, to reduce the 
possibility of protein degradation and facilitate the intact recombinant proteins 
isolation.  
 
A modified pET26(+) vector (Novagen, Nottingham, UK), pSANG10-3F vector can 
be used for recombinant protein and antibody expression. This vector is under control 
of the T7/lac promoter and the Lac repressor, encoded by the lacI gene, to control the 
basal expression of the protein (Figure 1.4). The T7 promoter requires a DE3 
lysogenic strain such as the BL21(DE3) strain, which contains an integrated T7 RNA 




Figure 1.4 Schematic view of the expression cassettes of the pSANG10-3F vector. The protein 
encoding genes are sub-cloned at the NcoI/NotI sites. Picture is adapted from (Martin et al., 2006). 
 	  
1.11.2  ScFv Expression in E. coli 
 
A single chain antibody (scFv) is a combination of variable light and heavy chains 
joined via a soluble (serine) and flexible (glycine) polypeptide linker. This small 
active fragment of approximately 27 kDa in size retains the whole antibody binding 
site (Huston et al., 1991, Sanchez et al., 1999, Plueckthun, 1991).   
 
a.  Disulfide Bond Formation 	  
Stable disulfide bond formation is required for many proteins such as scFv’s to allow 
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the protein to fold in a proper native conformation to enhance the protein solubility or 
activity. In the absence of disulfide bonds, these proteins may form inclusion bodies 
or degrade. Disulfide bond formation normally occurs only when the protein is 
exported into the periplasmic space, which explains why the first successful 
expression of the active antibody fragments in E. coli, was obtained from the 
periplasm. This approach is still commonly used to produce scFv antibodies in  
E. coli (Guglielmi and Martineau, 2009, Kipriyanov, 2002). 
  
An alternative approach to produce scFv antibodies in E. coli is to express them in 
the cytoplasm (Martineau and Betton, 1999, Philibert and Martineau, 2004, 
Guglielmi and Martineau, 2009).  
 
Bacterial strains such as AD494, BL21trxB, Origami, Origami B, Rosetta-gami™, 
which carry mutations in glutathione reductase (gor) and/or thioredoxin reductase 
(trxB) can improve disulfide bond formation in E. coli cytoplasm (Prinz et al., 1997, 
Bessette et al., 1999, Ritz and Beckwith, 2001). Several strains such as  
Rosetta-gami(DE3) strains carry both trxB and gor mutations. These strains are 
capable of enhancing the disulfide bond formation and eventually a better solubility 
and activity compared to strains with only trxB mutation (Bessette et al., 1999).  
 
b.  Rare Codons 
 
There is more than one codon for most amino acids, and each organism carries its 
own bias in the usage of 61 available amino acid codons. In  
E. coli codons such as Arginine (Arg), Leucine (Leu), Isoleucine (Ile), Glycine (Gly), 
and Proline (Pro) are rarely used and therefore this must be taken into account when 
designing proteins for over-expression. 
 
To improve the expression of eukaryotic proteins in E. coli, strains such as Rosetta  
(derived from the BL21 lacY1 mutant Tuner™ strain) have been designed that 
contain codons rarely used in E. coli (Novy et al., 2001, Brinkmann et al., 1989, 
Seidel et al., 1992, Kane, 1995, Kurland and Gallant, 1996).  These strains also carry 
a chloramphenicol resistance plasmid that provides tRNAs for the AUA, AGG, AGA, 
CUA, CCC, GGA codons (Novy et al., 2001).  
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For scFv antibody expression in E. coli cytoplasm using the Rossetta gamiB(DE3) 
strain a designed expression plasmid such as pAHAHis (a modified pET32a(+) 
plasmid) can be used.  This plasmid is under control of the T7/lac promoter and the 
Lac repressor, encoded by the lacI gene, to control the basal expression of the protein 




Figure 1.5  Schematic view of the expression cassettes of the pAHAHis vector. pAHAHis vector is 
constructed using pET32a(+) vector as backbone. The single-chain antibody encoding genes are sub-
cloned at the NcoI/NotI sites.  
 
 
1.12  Pantoea & Paratransgenesis 
 
Pantoea is a rod-shapped, Gram negative, flagellated, non-capsulated and non-
sporulating bacterium belonging to the Enterobacteriaceae family with dimensions of 
0.5 to 1.0 to 3.0 µm. This bacterium may or may not produce yellow pigmented 
colonies (Gavini et al., 1989).  	  
1.12.1  Pantoea agglomerans 
 
Pantoea agglomerans, also formally known as Enterobacter agglomerans (Gavini et 
al., 1989), Erwinia herbicola, Ewing and Fife, is a Gram negative plant epiphyte 
(Lindow and Brandl, 2003, Andrews and Harris, 2000). 
 
This bacterium has been isolated from plant surfaces, seeds, water, animals (Gavini et 
al., 1989) and different insect species (Dillon and Charnley, 2002, Lindow and 
Brandl, 2003, Loncaric et al., 2009, Andrews and Harris, 2000). 
  
Pantoea agglomerans strains are one of the most promising biocontrol agents for a 
variety of bacterial and fungal plant diseases. This bacterium has been used as a 
biological control agent for pome and citrus fruits pathogens particularly against fire 
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blight (Costa et al., 2002). Thus it may be an important paratransgenic tool for 
controlling other diseases such as Pierce's Disease (Pusey, 2002, Rio et al., 2004). 
 
Bisi and Lampe (2011) reported a successfully engineered P. agglomerans expressing 
and secreting Plasmodium effector proteins to inhibit development of malaria 
parasites (Plasmodium spp.) in the mosquito gut environment. They have reported 
that two secretion signals, pelB and hlyA, were used and tested for their ability to 
secrete anti-Plasmodium effector protein in both E. coli and P. agglomerans. Effector 
proteins with a HlyA fusion were successfully secreted in P. agglomerans and  
E. coli, however neither of these antibodies showed activity in an ELISA assay.  The 
strains that secreted antibodies are under evaluation for anti-Plasmodium activity in 
infected mosquitoes. It was also reported that under laboratory conditions the strains 
that secreted the effector proteins grew as well as wild-type strains, which may be 
competitive with the native microbiota in the environment of the mosquito midgut 
(Bisi and Lampe, 2011). 
 
1.12.2  Alternative Organisms 
 
Recently it has been reported that expression of a recombinant antibody against 
Plasmodium falciparum sporozoite surface protein (Chappel et al., 2004a, Chappel et 
al., 2004b) via an engineered entomopathogenic fungus, reduced the levels of  
P. falciparum sporozoite in Anopheles gambiae (Fang et al., 2011) . In this study a 
surface accessible highly abundant protein, the circumsporozoite protein was targeted 
by the recombinant antibody and was designed to agglutinate the parasite. This 
approach is independent of disrupting host cell specific interactions and may be a 
general strategy against targets that are present at high density on the pathogen 
surface.  
 
Recombinant antibodies against MopB and other abundant surface exposed 
molecules on X. fastidiosa could readily be engineered to agglutinate the bacteria and 
introduced into the GWSS via paratransgenic organisms such as engineered 
Metarhizium spp (Fang et al., 2011) or Beauvaria bassiana (Bukhari et al., 2011) and 
an avirulent strain of Xylella itself (Miller, 2011). 
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1.13  Justification and Rationale of the Project 
 
It is more than a decade that X. fastidiosa was identified as causal agent of many plant 
diseases in USA. One of the major agriculture problems in California is Pierce’s 
Disease. This disease, which damages the production of wine, table and raisin grapes, 
is the result of interaction of the plant host (Vitis vinifera), a vector insect (GWSS) 
and the pathogen (X. fastidiosa). Significant efforts have been made to better 
understand, monitor and control this disease, but until now there is no efficient control 
measure available for PD. 	  
To minimise the losses of plants by Pierce’s Disease, various measures have been 
developed and classified as cultural, chemical, biological or strain improvement 
(Hopkins and Purcell, 2002). 
 
A novel avenue towards PD management is to target the causative agent of the 
disease, X. fastidiosa. The main purpose of this strategy would be to disrupt the 
transmission of the pathogen from the insect vector into the xylem vessels of 
grapevines. X. fastidiosa could be competitively displaced by another manipulated 
microorganism, which express and secrete an anti-Xylella factor in the same niche. 
The knowledge of genomic information of X. fastidiosa may provide efficient 
candidate targets for anti-Xylella factors such as surface exposed components that 
may potentially play a role in bacterial pathogenicity and will present opportunities 
for developing diagnostic and paratransgenic applications to track, manage and 
potentially control PD either in the GWSS or the plant. 
 
1.14  Aim of the Project 
 
The aim of this project is to isolate recombinant single chain Fv fragments against  
X. fastidiosa surface exposed antigenic MopB protein from mice spleens previously 





1.15  Project’s Objectives 
 
The main objectives involved in this project are presented as follows:  
- To prepare recombinant MopB protein 
- To evaluate immune murine sera for anti-MopB activity 
- To construct mouse single-chain antibody libraries 
- To select specific antibodies using ribosome display technology 
- To express selected antibodies in E. coli  
- To engineer Pantoea agglomerans to express selected recombinant antibody 
 
In this project, to isolate recombinant single chain Fv fragments against X. fastidiosa 
surface exposed antigenic MopB protein from mice spleen previously immunized with 
whole heat killed X. fastidiosa, an outer membrane protein MopB (Fjellbirkeland et 
al., 2000, Morano et al., 2008), which is partially exposed on the surface of the X. 
fastidiosa bacterium has been chosen as a target protein for creating anti-Xylella scFv 
antibodies. The X. fastidiosa MopB gene will be engineered permitting protein 
expression of two protein constructs (the full length mature and the truncated MopB) 
in the E. coli cytoplasm. The recombinant MopB protein will be used to evaluate 
mouse sera previously immunized with heat-killed X. fastidiosa. Then the antibody 
library will be assembled from immunoglobulin genes rescued from the same X. 
fastidiosa immune mouse spleens and used in an in vitro ribosome display to isolate 
scFv’s against recombinant MopB proteins. The selected scFv’s anti-MopB will be 
expressed in E. coli, purified and evaluated by functional analysis (Western blot, 
ELISA and Immunofluorescence Analysis). Furthermore, Pantoea agglomerans will 









































Chapter 2: Materials and Methods 
 
2.1  Molecular Biology Reagents/Kits 
 
MP biomedicals, Illkirch, France  
Taq & Go Ready to Use PCR Mix. 
 
New England Biolabs, Hitchin, Herts, UK 
10X T4 DNA ligase reaction buffer, 100 base pair (bp) and 1 Kb DNA ladder, 
Protoscript® First Strand cDNA Synthesis Kit, restriction endonucleases, T4 DNA 
ligase. 
 
Promega, Southampton, Hampshire, UK 
Bright-GLo Luciferase reagent, TNT®T7 Quick Coupled Transcription/Translation 
System.  
 
Qiagen, Crawley, West Sussex, UK 
Ni2+-NTA Spin Columns, QIAquick Gel Extraction Kit, QIAprep Spin Miniprep Kit, 
QIAexpress Kit, RNeasy Mini Protocol kit, One-stepTM (QIAGEN) RT-PCR. 
 
Roche Diagnostics Ltd., Burgess Hill, West Sussex, UK  
DNase I recombinant.  
 
Thermo Fisher Scientific, Loughborough, Leicestershire, UK 
 TOPO TA Cloning®Kit for Sequencing, TRIZOL®Reagent. 
 
2.2  Chemicals  
 
Becton, Dickinson and Company, Oxford, UK  
Bactotryptone, Yeast extract. 
 
BIO-RAD Laboratories Ltd., Hemel Hempstead, Hertfordshire, UK  
Precision plus protein dual Xtra standards.   
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GBIOSCIENCES, Maryland Heights, MO 63043-3202, U.S.A. 
Nickel chelating resin.  
 
Merck, Darmstadt, Germany  
5-bromo-4-chloro-3-indolyl phosphate (BCIP), Nitro blue tetrazolium (NBT).  
 
Sigma-Aldrich, Poole, Dorset, UK  
Agarose, β-mercaptoethanol, dithiothreitol, Diethylaminoethyl (DEAE)-dextran, Mg 
acetate, Monoclonal anti-polyHistidine-alkaline phosphatase antibody produced in 
mouse, rabbit anti-mouse antibody, rabbit anti-mouse alkaline phosphatase antibody, 
goat-anti-rabbit IgG alkaline phosphatase conjugate. 
 
Abcam, Cambridge, UK 
Anti-polyHistidine- fluorescein isothiocyanate (FITC) conjugate. 
 
Thermo Fisher Scientific, Loughborough, Leicestershire, UK  
5-bromo-4-chloro-3-indolyl-ß-D-galactopyranoside (X-gal), 96 well flat bottom 
opaque Nunc plate, acetic acid glacial, acrylamide: bis-acrylamide 29:1 solution  
40 %, ammonium persulfate, Bovine serum albumin (BSA), Bromophenol blue, 
CaCl2, carbenicillin, chloramphenicol, Coomassie brilliant blue R-250, 
Diethylpyrocarbonate (DEPC)-treated H2O, Dulbecco's modified Eagle medium 
(DMEM), F96 MaxiSorp Nunc-Immuno plate, glucose, glycerol, Glycine, guanidine 
hydrochloride, guanidine thiocyanate, Imidazole, Immobilon-P transfer membrane, 
Isopropyl β-D-1-thiogalactopyranoside  (IPTG), isopropyl alcohol, kanamycin, KCl, 
Luria Bertani (LB) agar, LB broth, methanol, MgCl2, MgSO4, NaCl, p-Nitrophenyl 
phosphate (pNPP), Sodium dodecyl sulphate (SDS), tetracycline, 
Tetramethylethylenediamine (TEMED), Tris base, Tween-20. 
 
2.3  Equipment  
 
BIO-RAD Laboratories Ltd., Hemel Hempstead, Hertfordshire, UK 




BMG Labtech, Aylesbury, UK      
FLUOstar OPTIMA.  
 
Clare Chemical Research, Dolores, USA 
Dark Reader Transilluminator DR-88X. 
 
Thermo Fisher Scientific, Loughborough, Leicestershire, UK  
Nanodrop 1000 Spectrophotometer.  
 
Molecular Devices, USA 
VersaMax ELISA Microplate Reader.  
 
Cole-Parmer Instrument Company Ltd, UK   
Thermo scientific MaxQ 4000 Benchtop shaker. 
 
New Brunswick, USA  
Innova43 incubator shaker series. 
 
DBJ Labcare, UK 
Hettich Centrifuge Universal 320/320R rotors: 1617 and 1689-A, SORVALL fresco 
Jencons pls.  
 
2.4  Oligonucleotide Primers and Plasmids 
 
All of the oligonucleotide primers (Table 2.1) were purchased from Invitrogen Life 
Technologies (Paisley, UK). pCR®II-TOPO vector (Invitrogen) was used for the 
cloning of PCR products.  
 
The pSANG10-3F vector for protein expression (Martin et al., 2006) was provided 
by Prof. John McCafferty (Department of Biochemistry, University of Cambridge). 
The pMALc2x_mopB plasmid was kindly provided by Dr. David Lampe. The 
pA2A10, pET32a(+)RFPHApeptHis, HA-phoAM, pBSK-CA19.9 and pBSKmCit 
plasmids were kindly provided by Professor Angray Kang. 
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Table 2.1 Primers (5’ to 3’ direction) used in PCR. Primers degenerate codons used for synthesising 
variable regions are: M=A/C; R=A/G; W=A/T; S=G/C; Y=C/T; K=G/T; V=A/G/C; H=A/C/T; 
D=A/G/T; B=G/C/T; N=A/G/C/T. 
 
  




Truncated MopB primer 
MopB-NdeMat ATACATATGGCCCAGGAATTCGATGACCGGTGGTATCTCGCTGG 
MopB-TrunNot GCATGCGGCCGCACCAAATGGGATCACGACACC  
 
 First strand cDNA 
Oligo-dT29VN TTTTTTTTTTTTTTTTTTTTTTTTTTTTTV 
MVHlink2 GGC AGC AGA TCC AGG GGC CAG TGG ATA GAC 
  






















MVHR1.1 GGA AAC TGT CGG TGC GGC CGC CGM RGA RAC DGT GAS HRD RG 







   VH-Linkers 
MVHFlink(Gly4Ser)2 GGCGGCGGCGGCTCCGGTGGTGGTGGTTC 
  
                                                                            Table 2.1 Continued on next page 
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Mouse Kappa Constant (MKC) 
MKNotCF CGGCGGCCGCACCGACAGTTT CC 
MKRev AGAAGCTTGCTCGAGGATTCG 
   
   T7 Promoter 
RDT7 CTATAGAAGGGTAATACGACTCACTATAG 
     Standard Sequencing Primers 
SP6 GATTTAGGTGACACTATAG 




2.5  Cell Culture 
 
Escherichia coli (E. coli) XL1-Blue [recA1 endA1 gyrA96 thi-1 hsdR17 supE44 
relA1 lac (F´ proAB lacIqZΔM15 Tn10 Tetr)] competent cells for plasmid 
manipulations were purchased from Stratagene (California, USA).  
 
E. coli BL21(DE3) [F– dcm ompT hsdS(rB– mB–) gal λ(DE3)], Rosetta gami B(DE3) 
[F– ompT hsdS B(rB– mB–) gal dcm lacY1 aphC(DE3) gor522::Tn10 trxB pRARE2 
(Cam R , Kan R , Tet R )] E. coli strain (Novagen) competent cells were used for 
recombinant protein expression.  
 
2.6  Chemically Competent Cells 
 
The Cohen method (Cohen et al., 1972) was used to prepare E. coli chemically 
competent cells (XL1-Blue, BL21(DE3) and Rosetta gami B(DE3)). Briefly, 10 µL 
of cells from glycerol stocks or 5 single colonies from an LB agar plate were 
inoculated into 10 mL of culture media containing the appropriate antibiotic and 
grown at 37 °C overnight. Pre-warmed LB medium (200 mL) supplemented with the 
appropriate antibiotic was inoculated with 10 mL of the overnight culture, and grown 
at 37 °C with vigorous shaking 250 rpm, until the OD600 reached between 0.4 - 0.5 
and immediately placed on ice for 30 minutes. The cells were pelleted by 
centrifugation at 1000 g and 4 °C for 7 minutes in pre-chilled sterile falcon tubes. The 
cell pellets were re-suspended in 0.1 M MgCl2 (50 mL for 200 mL of cell culture) 
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and the pelleting procedure repeated. The resultant cell pellet was re-suspended in  
0.1 M CaCl2 (100 mL for 200 mL of cell culture), incubated on ice for 30 minutes 
and pelleted as described earlier. The cells in the final pellet were gently  
re-suspended in 4 mL of 0.07 M CaCl2 containing 15 % glycerol (2.8 mL of 0.1 M 
CaCl2 and 1.2 mL of 50 % glycerol) and 50 µL aliquots stored at –80 °C. 
 
2.7  E. coli Transformation  
 
E. coli transformation was performed using the Hanahan method (Hanahan, 1983) 
with modifications. In brief, competent cells (50 µL) were thawed on ice for 5 
minutes. The appropriate ligation mixture or plasmid was then added to the cells and 
incubated for 5 minutes on ice; the cells were heat shocked at 42 °C in a water bath 
for 1 minute, and then placed on ice for 5 minutes. Then 250 µL of pre-warmed (37 
°C) SOC (20 mg/mL Bactotryptone, 5 mg/mL Yeast extract, 10 mM NaCl, 2.5 mM 
KCl, 10 mM MgSO4, 10 mM MgCl2, 0.4 % glucose, pH 7.0) was added and further 
incubated at 37 °C with shaking at 250 rpm for 1 hour. The whole mixture was plated 
on LB agar plates containing appropriate antibiotic and incubated at 37 °C overnight. 
 
2.8  Colony PCR 	  
After transformation, colony PCR was used to screen the colonies for the desired 
plasmid. In brief, 2-3 different colonies were randomly picked and each colony was  
re-suspended in 10 µL of DEPC-treated water (RNase–free). Then 1 µL of each  
re-suspended colony was used in a PCR reaction with specific primers, which 
generated the PCR product of known size. Any colony that gave rise to an 
amplification product of the expected size was likely to contain the correct DNA 
sequence. The rest of the re-suspended colony with the desired plasmid was used to 
prepare 10 mL overnight culture for plasmid purification. 
 
2.9  Isolation of Plasmid DNA 
 
Plasmid DNA was isolated from a 10 mL overnight E. coli culture using a 
QIAprep®Spin Miniprep Kit (Qiagen Ltd, UK) according to the manufacturer’s 
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instructions. In brief, a single colony from an LB agar plate or 10 µL of cells from the 
glycerol stock was inoculated into 10 mL of culture media containing the appropriate 
antibiotic and grown at 37 °C overnight. Next day a bacterial glycerol stock was 
prepared using 700 µL of overnight culture with 300 µL of 50 % glycerol and stored 
at -80 °C. Then, the rest of the culture (~9.3 mL) was centrifuged at 1000 g for 10 
minutes and the cell pellet re-suspended in 500 µL of P1 buffer (50 mM Tris-HCl, 10 
mM EDTA, 50 µg/mL RNase, pH 8.0). Two 250 µL aliquots were transferred into 
separate 1.5 mL microcentrifuge tubes. Cells in each tube were lysed by the addition 
of 250 µL of P2 buffer (0.2 M NaOH, 1% SDS) and gentle mixing by inversion 5 
times. To neutralise the mixture, 350 µL of N3 buffer (4 M guanidine hydrochloride, 
0.5 M potassium acetate, pH 4.2) was added to each tube and the tubes were mixed as 
before. The mixtures were centrifuged at 13,000 g for 10 minutes, and the 
supernatants were carefully transferred onto two QIAprep spin columns and 
centrifuged at 13,000 g for 1 minute. Then the columns were washed with 750 µL of 
PE buffer (20 mM NaCl, 2 mM Tris-HCl, 80 % ethanol, pH 7.5) and the flow-
through was discarded. The columns were centrifuged again at 13,000 g for 1 minute 
to remove residual wash buffer. Purified DNA was eluted by adding 30 µL of DEPC-
treated H2O to each column and centrifuged at 13,000 g for 1 minute and stored at  
-20 °C.  
 
2.10  Gel Electrophoresis  	  
DNA samples (plasmids, digested fragments and PCR products) were resolved by gel 
electrophoresis with 2 % or 1 % (w/v) agarose depending on the DNA fragment size 
and 0.5 µg/mL ethidium bromide at 100 V for 1 hour. The gel was visualised with a 
transilluminator using short wavelength UV light (254 nm) after electrophoresis. The 
DNA fragment sizes were determined by comparison with 100 bp DNA or 1 kb 
ladder.  	  
2.11  Gel Extraction 	  
For DNA purification from agarose gels, the piece of gel containing the desired DNA 
fragment was excised with a clean scalpel using long wavelength UV light (366 nm) 
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under Dark Reader Transilluminator DR-88X to reduce ultraviolet (UV) DNA 
damage. The DNA was purified from the gel using QIAquick Gel Extraction Kit 
according to the manufacturer’s instructions. Briefly, excised agarose gel was 
dissolved in 300 µL of QG buffer (5.5 M guanidine thiocyanate, 20 mM Tris-HCl, 
pH 6.6) and incubated at 50 °C for 10 minutes. The solution was mixed with 100 µL 
of isopropyl ethanol before loading on a QIAquick spin column and centrifuge at 
13,000 g for 1 minute. The column was washed with 750 µL of PE buffer (20 mM 
NaCl, 2 mM Tris-HCl, 80 % ethanol, pH 7.5) and centrifuged at 13,000 g for 1 
minute. DNA was eluted in 30 µL of DEPC-treated H2O and stored at -20 °C. 
 
2.12  Bespoke Protein Marker 
 
The protein markers, which were used to calibrate SDS-gels and Western blot, were 
based on purified recombinant proteins prepared in the laboratory of Professor Kang. 
The Bespoke marker was a mixture of four different recombinant proteins with  
His-tag fusion:  
1) Thioredoxin (TRX) protein in pET32a plasmid (20 kDa). 
2) Red Fluorescent Protein (RFP) in pSANG (30 kDa). 
3) Full length mature MopB protein in pSANG (42 kDa).  
4) Heat Shock Protein (HSP) 70 in pET16b (75 kDa).  
These protein standards were compared with commercial Precision Plus Protein Dual 
Xtra standards in SDS-PAGE and Western blot to confirm utility.  
 
2.13  SDS-PAGE 
 
Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) was 
carried out using Laemmli system (Laemmli, 1970) with modifications (Markiv et 
al., 2011). 
 
In brief, to analyze the protein a 12 % resolving gel (12 % acrylamide/bis (29:1), 360 
mM Tris base, 0.1 % SDS, 0.1 % ammonium persulphate, 0.1 % TEMED, pH 8.8) 
and 4 % stacking gel (4 % acrylamide/bis (29:1), 60 mM Tris base, 0.1 % SDS, 0.1 % 
ammonium persulphate, 0.1 % TEMED, pH 6.8) were prepared. The cleaned glass 
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plates and spacers (0.75 mm thickness) were assembled in a gel holder on a casting 
stand (Mini-Protean II electrophoresis system). The ingredients for the gels were 
prepared according to the proportions above, 3.5 mL of resolving gel mixture was 
poured between the glass plates for each gel, overlaid with water and left to 
polymerise for 5-10 minutes. The water was poured off and the procedure was 
repeated for the 4 % stacking gel. The protein samples were prepared by mixing  
15 µL of the purified protein fractions with 5 µL of 4X sample loading buffer (62.5 
mM Tris base, 2 % SDS, 5 % β-mercaptoethanol, 0.05 % Bromophenol blue, 10 % 
glycerol, pH 6.8). The un-induced and induced samples were prepared by adding  
50 µL 4X sample loading buffer to the cell pellets. The prepared samples were then 
heated for 5 minutes at 100 °C, centrifuging briefly and loaded on the gel.  
 
Electrophoresis was performed using a Mini-Protean II electrophoresis system, with 
running buffer (25 mM Tris base, 192 mM glycine, 0.1 % SDS). The gel was run for 
45 minutes at 200 V. Resolved proteins were visualised by staining the gel in  
0.025 % w/v Coomassie Brilliant Blue R-250 (Bio-Rad Laboratories) (Meyer and 
Lamberts, 1965) in 10 % v/v acetic acid, and heating for approximately 1 minute in a 
microwave and allowed to cool for 2 minutes followed by destaining by placing in 
fresh 10 % acetic acid solution and heating as before. The gels were kept in 10 % 
acetic acid (Markiv et al., 2011). 
 
2.14  MopB Protein Expression and Purification 
     
2.14.1  Recombinant MopB Protein 
 
The complete amino acid sequence of X. fastidiosa Temecula1 strain (NCBI 
Reference Sequence: NP_779898.1) MopB was submitted to web based protein 
prediction programs, SIG-Pred: signal peptide prediction 
(http://bmbpcu36.leeds.ac.uk/prot_analysis/Signal.html) (Bradford, 2001)  and to the 
PRED TMBB website, which hosts a Hidden Markov Model method, capable of 
predicting transmembrane beta-strands of outer membrane proteins of Gram negative 
bacteria (http://biophysics.biol.uoa.gr/PRED-TMBB/) (Bagos et al., 2004a, Bagos et 
al., 2004b, Spyropoulos et al., 2004) to identify the signal peptide and the putative 
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surface exposed domains respectively.  
	   
The predicted encoded mature form of full-length MopB (MopB 355) consisting of 
the outer membrane and the periplasmic domain, without the leader sequence and the 
N-terminal β-barrel trans membrane domain (MopB 182) without the leader sequence 
were PCR amplified using primers (MopB-NdeMat and MFNOTR) designed to 
include NdeI (5’) site encoding an in-frame methionine start codon and NotI (3’) site 
encoding in-frame triple alanine (primers are listed in Table 2.1). The MopB 
constructs were amplified using Taq & Go polymerase using pMALc2x_mopB 
template. The PCR amplifications were carried out using 16 cycles consisting of  
95 °C (30 seconds), 52 °C (30 seconds), and 72 °C (1 minute) after the last cycle a 
further incubation at 72 °C for 10 minutes, then cooled to 8 °C. To confirm the 
presence of amplified products, the samples were resolved by gel electrophoresis 
with 2 % (w/v) agarose and then the desired DNA fragment was excised from the gel 
and purified using QIAquick Gel Extraction Kit as described in sections 2.10 and 
2.11. 
 
The PCR products and the expression vector (pSANG 10-3F) were restricted with 
NdeI and NotI using	  30 µL of purified DNA from the above step with 5 units of each 
restriction enzyme NdeI and NotI in the presence of 1X NEBuffer 3, 
100 µg/mL BSA and H2O to a final volume of 50 µL. The reaction mixture was 
incubated at 37 °C for 2 hours.  
 
The DNA fragments were subjected to electrophoresis in a standard 1 % agarose gel 
for the pSANG 10-3F backbone and 2 % agarose gel for the MopB fragments to 
confirm the presence of the DNA fragments. A 1 kb DNA ladder was used for 1 % 
agarose gel and 100 bp ladder was used for 2 % agarose gel. The DNA fragments 
were purified from the gel as described in sections 2.10 and 2.11. The MopB 
fragments were ligated into pSANG 10-3F vector using T4 ligase, which encodes the 
protein with an in-frame C-terminal sequence (Ala Ala Ala Ser Ala (His)6 Lys Leu 




The ligation reactions were set up by mixing 7 µL of purified insert, 1 µL of purified 
vector pSANG10-3F, 1 µL containing 20 units of T4 DNA ligase and 1 µL of 10X 
T4 DNA ligase reaction buffer making up to a final volume of 10 µL. The same 
transformation was also performed without the plasmid and unligated restricted NdeI 
and NotI pSANG 10-3F vector as the ligation controls. The reaction mixture was 
incubated at room temperature for 2 hours and was transformed into chemically 
competent XL1-Blue cells (section 2.7) and cultured overnight at 37 °C in LB plates 
containing 30 µg/mL kanamycin. The colonies were checked by colony PCR and 
positive colonies for the two MopB constructs were separately inoculated overnight 
in 10 mL of LB media with 30 µg/mL of kanamycin for plasmid extraction as 
described in sections 2.8 and 2.9.  
 
The recombinant plasmids were sequenced at the Wolfson Institute for Biomedical 
Research (WIBR), University College London using Applied Biosystems BigDye3.1 
sequencing chemistry, running on an AB3730XL capillary sequencer. 
 
2.14.2  MopB Protein Expression in pSANG 10-3F Vector 	  
The sequence confirmed MopB in pSANG 10-3F plasmids (section 2.14.1) were used 
to transform BL21(DE3) E. coli cells (section 2.7) for protein expression. The 
molecular weight and isoelectric points was predicted using ExPASy bioinformatics 
resource portal (http://web.expasy.org/compute_pi/) (Gasteiger et al., 2003).  
 
Five fresh colonies were picked and grown in 10 mL LB medium containing  
30 µg/mL kanamycin at 37 °C, 250 rpm, for 16 hours and a 700 µL aliquot removed 
for preparation of a glycerol stock as described earlier in section 2.9. The remaining 
culture was used to inoculate pre-warmed 200 mL of the same medium, maintained at 
the same culture conditions until the OD600 reached between 0.4 - 0.6. As a control,  
1 mL aliquot of culture was collected and centrifuged at 13,000 g for 1 minute and 
the cell pellet was kept at -20 °C as un-induced sample. Expression of recombinant 
proteins was induced by the addition of isopropyl β-D-1-thiogalactopyranoside 
(IPTG) to a final concentration of 0.3 mM and cultivated for 3 hours at 37 °C with 
shaking at 250 rpm. Before harvesting the culture, a 1 mL aliquot of the induced 
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culture was collected and centrifuged at 13,000 g for 1 minute and the cell pellet was 
kept at -20 °C as induced sample for protein analysis. The culture was harvested by 
centrifuge for 20 minutes at 4000 g, 4 °C, and stored for further use at -20 °C.  
 
2.14.3  MopB Protein Purification 	  
a.  Purification using Denaturation Condition 	  
The cell pellets obtained from 200 mL liquid cultures (section 2.14.2) were  
re-suspended in 5 mL lysis buffer (6 M guanidine hydrochloride, 10 mM Tris–HCl, 
500 mM NaCl, 10 mM Imidazole, pH 8.0). The cells were lysed by sonication on ice 
(6x30 seconds with 30 seconds rest intervals), in an ultrasonic cell disruptor, and 
were centrifuged at 16,000 g for 45 minutes to remove cellular debris. The 
supernatant containing soluble cellular material were retained for the purification 
procedure.  
 
Recombinant protein was purified using Ni2+-NTA agarose affinity resin as described 
in The QIAexpressionistTM -- A handbook for high-level expression and purification 
of 6xHis-tagged proteins, fifth edition. A 10 mL column was packed with 1 mL of 
nickel chelating agarose resin and equilibrated with 5 mL wash buffer (8 M Urea, 10 
mM Tris–HCl, 100 mM NaH2PO4 pH 8.0). The supernatants containing the 6xHis-
tagged recombinant protein were loaded onto the equilibrated 1 mL Ni2+-NTA 
column. The flow through was collected and the Ni2+-NTA column was washed with 
5 mL of wash buffer (8 M Urea, 10 mM Tris–HCl, 100 mM NaH2PO4 pH 6.3). The 
bound recombinant fused proteins were eluted in 5X1 mL fractions using 5 mL of 
elution buffer (8 M Urea, 10 mM Tris–HCl, 100 mM NaH2PO4 pH 4.5). Fractions 
were assayed for total protein concentration and analyzed by SDS-PAGE (section 
2.13).  
 
b.  Purification using Native Condition 	  
The cell pellet obtained from 400 mL culture was re-suspended in 5 mL native lysis 
buffer (20 mM Tris–HCl, 500 mM NaCl, 20 mM Imidazole, 0.1 % Triton X-100 pH 
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8.0) and 400 µL lysozyme (1 mg/mL) was added. The cells were lysed by sonication 
on ice (6x30 seconds burst at 30 seconds intervals), in an ultrasonic cell disruptor and 
then centrifuged at 18,000 g for 45 minutes. The supernatant containing soluble 
cellular material was retained for purification procedure using an ÄKTAprime liquid 
chromatography system using a 1 mL HisTrap HP column fitted to an ÄKTAprime™ 
plus liquid chromatography system. The column was equilibrated with 5 mL wash 
buffer (20 mM Tris–HCl, 500 mM NaCl, 20 mM Imidazole pH 8.0).  
 
The soluble fraction containing the 6xHis-tagged protein was diluted two times with 
wash buffer (20 mM Tris–HCl, pH 8.0, 500 mM NaCl buffer) and loaded onto the 
equilibrated 1 mL Ni2+-NTA column. The flow through was collected and the column 
was washed with 5 column volumes of wash buffer (20 mM Tris–HCl, pH 8.0, 500 
mM NaCl, 20 mM Imidazole). The bound proteins (full length mature and truncated 
MopB fusion proteins) were eluted in 1 mL aliquots using 5 column volumes of 
elution buffer (20 mM Tris–HCl, pH 8.0, 500 mM NaCl, 500 mM Imidazole) and 
analyzed by SDS-PAGE (section 2.13).  
 
2.14.4  Protein Analysis  
 
a.  SDS-PAGE 	  
The SDS-PAGE was performed as described in section 2.13  
 
b.  Protein Concentration Determination 
 
Recombinant soluble protein concentrations were determined by using a Bradford 
dye bind protein assay kit.  
 
Protein standards were prepared in buffer ranging from 0.1-1.4 mg/mL using a BSA 
standard. Using a 96 well plate, 5 µL of the protein standards was added to separate 
wells and 5 µL of the buffer was added to the blank wells. The recombinant soluble 
protein was prepared with an approximate concentration between 0.1-1.4 mg/mL. To 
each well being used, 250 µL of the Bradford Reagent (0.01 % (w/v) Coomassie 
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Brilliant Blue G-250, 4.7 % (w/v) ethanol, 8.5 % (w/v) phosphoric acid) was added 
and mixed on a shaker for approximately 30 seconds. The samples were incubated at 
room temperature for 5 to 45 minutes. Then the absorbance was measured at 595 nm 
(The protein-dye complex is stable up to 60 minutes). The net absorbance vs. the 
protein concentration of each standard was plotted. 
 
2.14.5  Mouse Immunization 	  
Preparation of the  Xylella  fasitidosa and initial serum dot-blot analysis was carried 
out by Arinder Arora in the laboratory of Professor Thoma Miller at the University of 
California Riverside, USA. Briefly Xylella  fasitidosa (strain Temecula) was grown in 
100 mL PD3 (Davis et al., 1980) medium at 28 ºC on an orbital shaker at 180 rpm for 
10 days until the OD was 0.5 at 600 nm. The bacteria were pelleted and washed twice 
by re-suspension in 100 mL PBS and the final pellet wet weight determined. The 
final pellet was re-suspended in PBS at 10 mg/mL w/v and a 1 mL aliquot prepared. 
The aliquot was incubated at 28 ºC (viability; positive control) and the remainer at 55 
ºC for 1 hour. Samples were removed and plated out on PD3 agar and incubated for 
15 days to check for viability, the remainder of the bacterial pellet was frozen at -80 
ºC. Once it had been confirmed that no viable bacteria were present in the heat-
treated ampules, aliquots were sent to ProSci (Poway, CA USA) for immunization of 
Balb/c mice (n=5). The initial immunization (0.5 mL/mouse) was followed by 
boosting at weeks 4 , 8 and 12. Test bleeds were taken a weeks after the third 
boosting for Dot blot analysis and enzyme-linked immunosorbent assay (ELISA). 
Following testing, mice were boosted again and three days later underwent a 
splenectomy, each spleen was placed immediately in 10 mL of TRIZOL for use in 
RNA isolation. 
 
2.14.6  Bacterial Dot Blot 
 
To carry out the preliminary screening to determine whether the mice had mounted 
an antibody response to X. fastidiosa a Dot blot assay was devised. Thin strips of 
nitrocellulose ~5 mm wide were prepared and spotted with either 5 µL of 5 % w/v 
skimmed milk powder in PBS or 5 µL of bacterial suspension of E. coli or 5 µL  
 53	  
X. fastidiosa Temecula 1 strain allowed to air dry, blocked with 1% BSA (molecular 
biology grade Bovine Serum Albumin) in PBS, and incubated in immune sera (bleed 
3) diluted 1/20,000 in PBST with 1 % BSA for 1 hour. Following washing with  
PBS-T, and then incubated with rabbit anti-mouse alkaline phosphatase antibody 
(diluted 1/20,000 in 1 % BSA in PBST) for 1 hour, then washed as before and 
developed in substrate solution (0.02 %, BCIP (5-bromo-4-chloro-3-
indolylphosphate) and 0.03 % NBT (nitroblue tetrazolium) in 10 mL 100 mM Tris-
base, 100 mM NaCl, 5 mM MgCl, at pH 9.5) until the spots were visible. 
 
2.14.7  Recombinant MopB ELISA 
 
Enzyme-Linked Immunosorbent Assay (ELISA) was carried out using Nunc-Immuno 
plates. The 96 well plates were coated with 100 µL of a 10 µg/mL solution of 
recombinant purified truncated MopB protein in phosphate buffered saline (PBS) or 
100 µL of a solution containing 10 µg/mL of molecular biology grade Bovine Serum 
Albumin (BSA) in PBS pH 7.4 as negative control at 4 °C overnight. The next day, 
the wells were washed with PBS containing 0.05 % Tween-20 (PBST), dried and 
blocked with 200 µL of 2 % BSA/PBS at room temperature for 1 hour. Polyclonal 
sera from mice (n=5) previously immunized with whole heat-killed X. fasitidosa were 
diluted to 1/200, 1/2000 and 1/20,000 in PBS containing 0.05 % Tween-20 (PBST) 
added in duplicate to the wells (0.1 µL/well) and incubated at 37 ºC for 2 hours. The 
wells were washed with PBS containing 0.05 % Tween-20 (PBST) five times and 
100 µL of rabbit anti-mouse antibody (diluted 1/20,000 in 1 % BSA in PBST) was 
added and incubated at 37 °C for 2 hours. The wells were washed as before and goat-
anti-rabbit IgG alkaline phosphatase conjugate (diluted 1/40,000 in 1 % BSA in PBS) 
was added to the wells and incubated at 37 °C for 2 hours. The plates were washed as 
before with an additional final wash with PBS alone and developed with 1 mg/mL  
p-nitrophenyl phosphate in 0.2 M Tris buffer pH 8.0 (pNPP) at 37 °C for 30 minutes. 
The absorbance was measured at 405 nm using a spectrophotometer VersaMax 
ELISA Microplate Reader. Both sample and control were performed in duplicate. A 
threshold value of ≥ 0.1 was used as the cut-off value for detection of mouse sera 1-5 
binding to the recombinant truncated MopB protein.  
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2.15  Mouse Immunoglobulin Library Assembly 
 
Mouse single chain antibody libraries were constructed from the five X. fastidiosa 
immunized mice spleens in 10 mL TRIZOL stored at -20 °C in the form of VL-Link-
VH-Mouse Kappa Constant (MKC). 
 
Total RNA was first extracted from the corresponding mouse spleen. Then the 
extracted RNA was used to synthesis the first strand complementary DNA (cDNA) 
using immunoglobulin specific primers. The synthesized cDNA was used to amplify 
the immunoglobulin variable regions by PCR. Finally five mice single-chain antibody 
libraries were assembled individually by linking all individual variable regions  
(7 light chains and 10 heavy chains) for each mouse by PCR. Detailed procedures are 
described below.      
 
2.15.1  Total RNA Extraction 	  
The immunized mice spleens (section 2.14.5) were homogenized, disrupted and 
dissolved in 10 mL TRIZOL®Reagent and stored at -20 °C. Total RNA was isolated 
using TRIZOL®Reagent according to the manufacture’s instruction. In brief, 0.2 mL 
of chloroform was added for each mL of the homogenized mouse spleen in 
TRIZOL®Reagent. The sample was shaken vigorously by hand for 15 seconds and 
then incubated for 15 minutes at room temperature. The mixture was centrifuged at 
12,000 g for 15 minutes at 4 °C. Without disturbing the pellet the aqueous phase of 
the sample was transferred to a clean tube. The RNA was precipitated from the 
aqueous phase by adding 200 µl of 100 % isopropanol alcohol for each 1 mL of the 
sample, mixed by inversion and incubated for 15 minutes at room temperature. The 
sample was centrifuged at 12,000 g for 10 minutes at 4 °C. The supernatant was 
removed, leaving only the RNA pellet.  The pellet was washed with 1 mL  
75 % ethanol per 1 mL of sample, briefly vortexed and incubated for 5 minutes at 
room temperature. The sample was then centrifuged at 7500 g for 5 minutes at 4 °C.  
The supernatant was removed, the pellet was air dried at room temperature for 10 
minutes and re-suspended in 50 µL DEPC-treated water (RNase–free). The dissolved 
RNA samples were spectrophotometrically analysed at 260 nm/280 nm using a 
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NanoDrop apparatus to determine the concentration and the purity; the total RNA 
samples were stored at -20 °C until required. 
 
2.15.2  First Strand cDNA Synthesis  	  
First strand cDNA was synthesised from total RNA using a Protoscript First Strand 
cDNA Synthesis Kit with Oligo-dT29VN primer for light chain and MVHlink2 
primer for heavy chains (all primers are listed in Table 2.1) following the protocol 
provided with the kit. Briefly, 1 µg of total RNA was incubated at 70 °C for 5 
minutes with 25 pmol of primer, 40 nmol of deoxyribonucleotide triphosphate mix 
(dNTP) and sufficient DEPC-treated H2O to a final volume of 16 µL. The mixture 
was placed on ice for at least 30 seconds before adding 2 µL of M-MuLV Reverse 
Transcriptase Reaction Buffer (10X RT Buffer), 1 µL of M-MuLV Reverse 
Transcriptase  (25 units) and 1 µL of RNase inhibitor (10 units). The mixture was 
incubated at 42 °C for 1 hour, followed by 95 °C for 5 minutes to inactivate the 
enzymes. To degrade the remaining RNA, 1 µL of RNase H (2 units) was added to 
the mixture and incubated for 20 minutes at 37 °C. Finally the mixture was incubated 
at 95 °C for 5 minutes to inactivate the enzyme. The resulting 20 µL cDNA synthesis 
reaction was stored at -20 °C until required.  
 
2.15.3  Mouse Single-Chain Antibody Library Construction 	  
A single chain variable fragment antibody library was constructed for ribosome 
display as VL-link-VH-MKC (Mouse Kappa Constant). The PCR primers for library 
construction were based on published sequences described by Kettleborough and  
co-workers (Kettleborough et al., 1993), with minor modifications, and ordered from 
Invitrogen (all primers are listed in Table 2.1). Members of the light chain families 
were individually amplified by PCR using Oligo-T29VN cDNA template using 
combinations of MVKF1-7 with MVKR primers. Members of the heavy chain 
families were individually amplified by PCR using MVHlink2 cDNA template using 
combinations of MVHF1-10 and MVHR1.1 primers. The primers were designed to 
introduce NcoI restriction site to the 5′ ends of the VL and NotI restriction site to the 
3’ end of the VH.  
 56	  
The amplified light chain products were purified, pooled and an aliquot was subjected 
to another round of PCR amplification using MVKFlink and MVKRlink primers to 
introduce part of the T7 site and Kozak sequence (Kozak, 1987)  on the 5’ end and an 
overlap extension to facilitate annealing to the variable heavy chain libraries. The 
amplified heavy chain products were processed and modified in a similar manner 
using primers MVHFlink and MVHR1.1. The modified variable light and heavy 
chain products were combined and amplified using MVKFlink and MVHR1.1 
primers. A synthetic mouse kappa constant domain (optimised for E. coli codon 
usage, synthesised by Epoch Biolabs, Tx USA) was amplified using MKNotCF and 
MKRev primers. The mouse kappa constant (MKC) was joined to the VL-Link-VH 
combinations by a PCR overlap extension reaction using MVKFlink and MKRev 
(Figure 2.1).  
 
Finally the PCR product encoding all the variable light chains and heavy chains 
combinations were amplified with primers RDT7 and MKRev to produce the DNA 
encoding the anti-X. fastidiosa immunoglobulin scFv libraries. The PCR reactions 
were performed at 50-62 °C annealing temperatures (depending on the primer pairs) 
the initial amplification used 30 cycles and subsequent library assembly step used 16 
cycles with Taq DNA polymerase and 25 pmol of each primer pair per reaction. DNA 
fragments were separated by gel electrophoresis on 2 % (w/v) agarose gels (section 
2.10). DNA purification from agarose gels was carried out following Qiagen kit 






Figure 2.1 An illustration of the mouse immunoglobulin library assembly process showing the PCR 
amplification and assembly steps using mouse spleen total RNA. 
 
 
2.15.4  Cloning and DNA Sequencing 	  
The purified single chain antibody library product was cloned into pCR®II-TOPO 
vector using TOPO TA Cloning® Kit, Invitogen according to the manufacturer’s 
instructions; 4 µL of DNA was ligated into 1 µL of TOPO vector and 1 µL of salt 
solution (provided in TOPO TA Cloning® Kit for Sequencing) and incubated at room 
temperature for 1 hour. The ligation mix was used to transform XL1-Blue E. coli 
cells on X-gal plates (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) containing 
100 µg/mL of carbenicillin to select for disruption of the β-galactosidase, performing 
blue/white screening.  
 
Three white colonies were randomly picked and were inoculated in 10 mL of LB 
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media with 100 µg/mL of carbenicillin; plasmid DNA was isolated from E. coli 
(section 2.9) and sequenced at the Wolfson Institute for Biomedical Research 
(WIBR), University College London using standard primers, M13 (-20) and SP6 
(Table 2.1). 
 
2.16  In vitro Ribosome Display 
 
To select single-chain antibodies a modified eukaryotic ribosome display was used as 
outlined in the schematic in Figure 2.2 (He and Taussig, 2007) with slight 
modifications.  
 
The PCR generated DNA libraries of antibody coding genes derived from mice 
(section 2.15.3) were expressed in a rabbit reticulocyte lysate system (Promega’s 
TNT quick coupled transcription/translation system). An in vitro coupled 
transcription/translation was set up in a 0.5 mL PCR tube as follows: 40 µL TNT T7 
Quick Master Mix, 1 µL 1 mM methionine (both provided in the kit), 2 µL of DNA 
library (10 ng-1 µg), 1 µL DNA enhancer and 6 µL DEPC-treated H2O. The mixture 
was incubated at 30 °C for 90 minutes. DNase I recombinant, RNase-free (10000 
u/mL) was added to the TNT mixture and incubated at 30 °C for 20 minutes to 
degrade the input DNA. 
 
To select specific antibody fragments the 0.5 mL PCR tubes were coated with  
10 µg/mL of the recombinant truncated and full length mature MopB in 100 µL PBS at 
4 °C overnight. Protein coated tubes were washed with PBS and blocked with 100 µL 
of molecular biology grade Bovine Serum Albumin (BSA) in PBS (10 mg/mL) (New 
England Biolabs) for 1 hour at room temperature. 
 
The translation/transcription mixture (containing the protein-ribosome-mRNA (PRM) 
complexes) was added to the washed and blocked protein-coated tubes and incubated 
on ice for 1 hour. The PCR tubes were washed by filling once with PBS (0.5 mL) and 





Figure 2.2 A schematic of the steps involved in in vitro antibody ribosome display. The scFv antibody 
library DNA template is prepared flanked with a T7 sequence and mouse kappa constant sequence. 
The antibody library is transcribed to mRNA and translated to form antibody-ribosome-mRNA 
complex (ARM). The mixture is incubated with immobilised truncated MopB and the unbound 
components are removed by washing. The retained complexes are released and the mRNA reverse 
transcribed and amplified by PCR. The PCR products are cloned into TOPO vectors and recovered 
plasmids sequenced. Full-length in-frame sequences are sub-cloned into the pAHAHis vector for scFv 
production.   
 
The retained RNA was recovered using RNeasy Mini Protocol kit according to the 
manufacturer’s instructions. In brief, 350 µL buffer RLT was added to the tubes and 
mixed by pipetting. The mixture was directly added onto a QIAshredder column and 
centrifuged for 2 minutes at maximum speed. The flow through was collected and  
350 µL of 70 % ethanol was added and mixed well by pipetting. The sample was added 
onto the RNeasy mini spin column and centrifuged for 15 seconds at 8000 g. Then  
700 µL buffer RW1 was added onto the RNeasy column, and centrifuged for 15 
seconds at 8000 g to wash. The flow through was discard and 500 µL buffer RPE was 
added onto the RNeasy column and centrifuged for 15 seconds at 8000 g to wash. The 
flow through was discarded and another 500 µL buffer RPE was added onto the 
RNeasy column and centrifuged for 2 minutes at maximum speed to dry the RNeasy 
membrane. The RNeasy column was transferred into a fresh eppendorf tube and 30 µL 
of RNase-free water was directly pipetted onto the RNeasy membrane and centrifuged 
for 1 minute at 8000 g to elute. The extracted RNA was stored at -20 °C. 
 
The extracted RNA was used in a One-stepTM (QIAGEN) RT-PCR reaction with 
MVKFlink and MKRD2 primers to amplify the antibody encoding DNA.  
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One-StepTMRT-PCR recovery was carried out using 50 µL RT-PCR mixture as 
follows: 10 µL 5XQ Solution, 10 µL 5XBuffer, 2 µL dNTP mix, 10 µL DEPC-treated 
H2O, 5 µL forward primer, 5 µL reverse primer (25 pmol), 6 µL RNA template and  
2 µL enzyme. 
 
The mixture was thermally cycled as follows: 50 °C for 30 minutes, 95 °C for 15 
minutes, 35 cycle 94 °C for 30 seconds, 52 °C for 30 seconds, 72 °C for 1 minute,  
72 °C for 5 minutes and then kept at 8 °C. Recovered DNA was analyzed by gel 
electrophoresis as described in section 2.10. 
 
2.16.1  TOPO TA Cloning and DNA Sequencing 	  
The RT-PCR product from a single round of ribosome display was cloned into 
pCR®II-TOPO® vector (TOPO TA Cloning® Kits, Invitogen) according to the 
manufacturer’s instructions as described in section 2.15.4. Five white colonies were 
randomly picked, inoculated into 10 mL of LB media with 100 µg/mL of 
carbenicillin and grown overnight at 37 °C with 250 rpm shaking.  
 
The plasmid DNA was isolated and sequenced as described in section 2.15.4 using 
M13 (-20) and SP6 standard primers (Table 2.1) at the core facility at WIBR, 
University College London. 
 
2.17  MopB Selected scFv Cloning and Expression 	  
2.17.1  Expression Plasmid Construction 
 
Since the MopB antigen used in this study was cloned and expressed in a vector that 
introduced hexa-histidine and Tri-FLAG tag, an alternative antibody expression 
vector with a different detection tag was constructed to permit evaluation of single 
chain (scFv) antibody binding. A plasmid was constructed by modifying pET32a(+) 
to incorporate a carboxyl-terminal-tag peptide sequence derived from influenza virus 
hemagglutinin, HA tag (Asp Val Pro Asp Tyr Ala Ser: DVPDYAS) followed by a 
hexa-histidine-tag designated pAHAHis.  
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The recovered single chain antibodies encoding sequences were ligated into 
pAHAHis plasmid as NcoI/NotI fragments for cytoplasmic expression in Rosetta 
gami B(DE3) E. coli.  
 
a.  pAHAHis Plasmid Construction 
 
To construct pAHAHis plasmid, pA2A10 (the 2A10 antibody for NPNA malaria 
antigen) and pET32a (+)RFPHApeptHis (Figure 2.3a) plasmids were digested with 
XbaI and NotI restriction sites.  
 
The 2A10 antibody sequence (~750 bp) from pA2A10 plasmid and HA-His (~5 kb) 
from pET32a(+)RFPHApeptHis plasmid were ligated and transformed into XL1-Blue 
competent cells using LB agar plates (section 2.7) containing 100 µg/mL of 
carbenicillin.  
 
The 2A10HAHis plasmid construct was purified and confirmed by DNA sequencing 
(Figure 2.3b).  To prepare the pAHAHis backbone, the 2A10HAHis plasmid was 
digested with NcoI and NotI sites and the fragments were resolved by gel 
electrophoresis using 1 % (w/v) agarose gel and purified as described in sections 2.10 
and 2.11.  
 
The MopB scFv antibodies were digested with NcoI and NotI sites and were ligated 
into digested NcoI /NotI pAHAHis backbone to construct pAMopBscFvHAHis 
plasmid (Figure 2.3c).    
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a) 
                                    
 
                   b) 
 
 




Figure 2.3 pAHAHis expression plasmids constructions. a) pET32a(+)RFPHApeptHis; 
b) pA2A10HAHis; C) pA MopB scFv HAHis. 
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b.  Anti-HA Antibody (Alkaline Phosphatase), HA-phoAM 
 
The anti-HA (DVPDYAS peptide) scFv was fused to alkaline phosphatase (anti-HA 





Figure 2.4 pAHAphoAM plasmid construct. 
 
2.17.2  MopB scFv Cloning and Expression in pAHAHis Expression Vector 	  
The recovered single chain antibodies encoding sequences were ligated into 
pAHAHis plasmid as NcoI/NotI fragments for cytoplasmic expression in Rosetta 
gami B(DE3) E. coli. The expression plasmid was transformed into XL1-Blue E. coli 
cells as described earlier in section 2.7, and plated onto LB agar plate containing with 
100 µg/mL of carbenicillin. A single colony was inoculated into 10 mL of LB 
medium with 100 µg/mL of carbenicillin and grown at 37 °C with 250 rpm shaking 
for 16 hours. pAHAHis encoding the scFv plasmid was isolated from E. coli, 
confirmed by sequencing and subsequently transformed into Rosetta gami B(DE3) 
competent cells (section 2.7), plated onto LB agar plate with 100 µg/mL of 
carbenicillin and 34 µg/mL of chloramphenicol, and grown at 37 °C for 16 hours. 
Next day, five colonies were inoculated in 10 mL of LB media with the same 
antibiotics and grown at 37 °C with 250 rpm shaking for 16-18 hours. The 10 mL 
overnight culture was used to prepare a glycerol bacterial stock as described 
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previously in section 2.9 and inoculated into 200 mL of LB medium containing the 
same antibiotics and grown at 37 °C with shaking at 250 rpm until OD600 reached 
between 0.4-0.6. The cells were then placed on ice for 30 minutes, induced by the 
addition of IPTG (final concentration 1 mM) and were incubated for 20 hour at 20 °C 
with shaking.  Cells were harvested in 4x50 mL tubes by centrifugation at 4000 g,  
4 °C for 20 minutes. Cell pellets were frozen and stored at -80 °C before undergoing 
further processing. 
 
2.17.3  Anti-MopB scFv Purification 	  
The cell pellets from 200 mL culture were used for purification using denaturing and 
native conditions.  
 
a.  Denaturing Conditions 
 
The 50 mL cell pellet from 200 mL culture was re-suspended in 3 mL of lysis buffer 
(6 M guanidine hydrochloride, 10 mM Tris–HCl, 500mM NaCl, 10 mM Imidazole, 
pH 8.0). Cells were lysed by sonication on ice (6x30 seconds), and were centrifuged 
at 14,000 g for 15 minutes to remove cellular debris. The supernatant containing the 
hexa-histidine-tagged recombinant protein were used for the purification procedure. 
Recombinant protein was purified using 1 mL of nickel chelating resin 
(GBiosciences) packed in a MicroSpin column. Then the columns were equilibrated 
with 600 µL lysis buffer (6 M guanidine hydrochloride, 10 mM Tris–HCl, 500 mM 
NaCl, 10 mM Imidazole, pH 8.0), and centrifuged at 890 g for 2 minutes. 
 
The supernatants containing the 6xHis-tagged recombinant protein were loaded onto 
the equilibrated 1 mL Ni2+-NTA column and centrifuged at 270 g for 5 minutes. The 
flow throughs were collected and the Ni2+-NTA column was washed two times with 
600 µL of wash buffer (8 M Urea, 10 mM Tris–HCl, 100 mM NaH2PO4 pH 6.3) at 
890 g for 2 minutes. The bound recombinant fused proteins were eluted into  
5X100 µL fractions using 500 µL of elution buffer (8 M Urea, 10 mM Tris–HCl,  
100 mM NaH2PO4 pH 4.5) at 890 g for 2 minutes. Purified proteins were stored at  
4 °C until required. 
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b.  Native Conditions 
 
The purification was performed under denaturing conditions as described above; but 
in this case native lysis buffer (20 mM Tris–HCl, 500 mM NaCl, 20 mM Imidazole,  
0.1 % Triton X-100 pH 8.0) with 75 µL lysozyme (1 mg/mL), native wash buffer  
(20 mM Tris–HCl, 500 mM NaCl, 20 mM Imidazole pH 8.0) and native elution 
buffer (20 mM Tris–HCl, 500 mM NaCl, 500 mM Imidazole, pH 8.0) were used. The 
purified protein fractions were kept at 4 °C.   
 
2.17.4  Expression and Purification of 2A10 and HA-phoAM scFvs  
 
The constructed pA2A10HAHis and HA-phoAM (anti-HA scFv antibody) plasmids 
were transformed into Roseta gamiB(DE3) competent cells and were expressed and 
purified as described earlier for selected MopB scFv antibody in pAHAHis plasmid 
(section 2.17.2 and 2.17.3). Purified proteins were stored at 4 °C until required. 
Fractions were assayed by SDS-PAGE as described before in section 2.13.  
 
2.17.5  Anti-MopB scFv Protein Analysis  	  
a.  SDS-PAGE 
 
The SDS-PAGE was performed as described in section 2.13.  	  
b.  Western Bloting 
 
Purified selected MopB scFv’s were blotted onto polyvinylidene difluoride (PVDF) 
membrane using a Mini Trans-Blot Cell (Bio-Rad) at 100 V for 1 hour with Western 
blot buffer (25 mM Tris base, 192 mM glycine, 20 % methanol) (Towbin et al., 
1979). PVDF membranes were blocked in 5 % w/v skimmed milk powder in Tris 
buffered saline (TBS: 50 mM Tris base, 150 mM NaCl pH 7.4) at room temperature 
for 1 hour, then incubated with monoclonal anti-polyHistidine-alkaline phosphatase 
antibody (diluted 1/10,000 in 5 % Milk/TBS) at room temperature for 1 hour on a 
rocking platform, followed by washing with 10 mL TBS-T (50 mM Tris base, 150 
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mM NaCl, 0.1% Tween-20, pH 7.4) 3x for 5 minutes each, then rinsed once with 
TBS (5 minutes) and the membrane developed by adding 10 mL of substrate (0.02 %, 
BCIP (5-bromo-4-chloro-3-indolylphosphate) and 0.03 % NBT (nitroblue 
tetrazolium) in 10 mL alkaline phosphates buffer (100 mM Tris-base, 100 mM NaCl, 
5 mM MgCl, 0.05 % Tween-20, pH 9.5). 
 
2.17.6  Anti-MopB scFv Functional Assays 
 
Antibody binding to recombinant truncated and full length mature MopB was 
examined by Western blot, ELISA and Immunofluorescence analysis. 
 
The scFv antibody binding to recombinant MopB was detected via the DVPDYAS 
peptide tag (HA tag). A secondary recombinant antibody was used where the anti- 
DVPDYAS peptide scFv was fused to alkaline phosphatase (anti-HA scFv-phoAM). 
 
a.  Western Blot 
 
Purified recombinant truncated and full length mature MopB were blotted onto PVDF 
membrane using a Mini Trans-Blot Cell (Bio-Rad) as described in section 2.17.5.  
PVDF membranes were blocked in 5 % milk in TBS with 0.097 % NaN3 at room 
temperature for 1 hour. The selected scFv for MopB after the first round ribosome 
display was used as the primary antibody (diluted 1/10 in 1 % milk/TBS 0.097 % 
NaN3) incubated for 6 hours at 4 ºC, then incubated with secondary antibody, purified 
anti-HA-phoAM antibody alkaline phosphatase conjugate (diluted 1/10 in 1 % 
milk/TBS NaN3) incubated at 4 ºC overnight and detected using BCIP/NBT substrate 
solution as described earlier in section 2.17.5. 
 
b.  ELISA 
 
Ninety-six well Nunc-Immuno plates were coated with either full-length mature or 
truncated MopB as described earlier with modification using 5 % w/v skimmed milk 
powder in TBS containing 0.097 % NaN3 instead of BSA as a negative control.  
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Purified antibodies, selected antibody for MopB, and negative control (2A10 
monoclonal antibody for NPNA repeat malaria antigen), were diluted 1/10 using 
TBS/NaN3 and incubated in the wells at 4 °C for 6 hours. The plate was washed with 
TBST for 5 times before adding the secondary antibody, purified anti-HA-phoAM 
antibody (1/10 diluted in 1 % milk/TBS NaN3) at 4 °C overnight. The assay was 
developed with p-nitrophenyl phosphate (pNPP) as described in section 2.14.6. A 
threshold value of ≥ 0.1 was used as the cut-off value for detection of 4XfMopB3 HA 
scFv binding to mature full and truncated MopB protiens. 
 
c.  Immunofluorscence Analysis 
 
The pellet from a 1 mL culture of heat-killed whole X. fasitidosa was  
re-suspended in 50 µL PBS and 10 µL of the spread on 3 glass slides, air dried and 
heat fixed by passing over a flame and blocked with 2 % w/v milk in PBS for 30 
minutes. Purified scFv antibodies (selected antibody for MopB and 2A10 antibody as 
control) were diluted 1 in 10 with 1 % w/v skimmed milk powder in PBS. The slides 
were incubated with either the anti-MopB antibody, anti-NPNA antibody (negative 
control), or without scFv for 1 hour. After washing with PBS, anti-polyHis-
fluorescein isothiocyanate (FITC) conjugate (1/10,000 dilution in 1 % milk/PBS) was 
added. The slides were incubated for 1 hour at ambient temperature in the dark. 
Slides were washed with PBS and viewed under oil immersion on an Axioscop 50 
fluorescence microscope (Zeiss) equipped with appropriate filter set for the detection 
of FITC (excitation at 450-480nm and emission at 510–550nm). Images were 
captured using a charge-coupled-device (CCD) camera (PowerShot digital camera; 
Canon) and AxioVision software (Zeiss).  
 
2.18  Engineering Pantoea agglomerans to Express Selected scFv Antibody 	  
2.18.1  Pantoea agglomerans Electro-Competent Cells 	  
The preparation of the competent cells was performed as described in section 2.6 
with slight modifications. The Pantoea agglomerans cells were grown at 30 °C until 
the OD600 was 0.4 - 0.5. Cells were harvested by centrifugation for 5 minutes at  
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5000 g at 4 °C in chilled sterile falcon tubes. Cells were re-suspended 2 times (2 
washes) in chilled MilliQ water and centrifuged for 10 minutes at 5000 g at  
4 °C. The cells were then re-suspended in 10 % glycerol and centrifuged for 10 
minutes at 4000 g at 4 °C. Cells were re-suspended again in 10 % glycerol (final 
volume 2 mL). The cells were stored in 80 µL aliquots at –80 °C. 
 
2.18.2  Antibiogram 	  
Susceptibility of Pantoea agglomerans was performed using a modified Kirby-Bauer 
disc diffusion method (Bauer et al., 1966). Briefly, 5 single colonies of Pantoea 
agglomerans from the LB agar plate were inoculated in 10 mL of fresh LB media 
grown at 37 ºC overnight. Next day, 100 µl of the overnight culture was spread onto 
agar plates using glass beads. The plate was allowed to dry for about 5 minutes.  
 
Individual antibiotic disks (OXIOD antimicrobial susceptibility test discs: Ampicillin 
10 µg, Tetracycline 50 µg, Neomycin 10 µg and Chloramphenicol 50 µg) were 
placed on the surface of the LB agar plate using flame-sterilized forceps and 
incubated for 16-18 hours at 37 ºC. Then the diameters of the inhibition zones were 
measured using a ruler. 
    
2.18.3  Electro-Transformation  
 
Eighty µL of electrocompetent cells were mixed with 7 µL DNA plasmid in a  
1-mm gapped electrocuvette (Bio-Rad), and subjected to a 1.8 kV pulse via the pulse 
controller (25 µF capacitor, 200 Ω external resistance) (Gene Pulser Xcell™, Biorad). 
Pulsed cells were mixed with 250 µL SOC (20 mg/mL Bactotryptone, 5 mg/mL 
Yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgSO4, 10 mM MgCl2, 0.4 % 
glucose, pH 7.0) and were incubated for 2 hours at 37 ºC with 200 rpm. Then the 
cells were plated to LB agar supplemented with the appropriate antibiotic. 	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2.18.4  pARM4 Plasmid 	  
Pantoea agglomerans is not resistant to ampicillin, tetracylin or kanamycin. To 
express selected recombinant MopB single chain antibody (scFv) in Pantoea 
agglomerans a plasmid with a constitutive promoter (lac promoter), pelB signal 
peptide and an in-frame C-terminal 6xHis-tag was assembled. 
 
a.  pARM4 Plasmid Construction  
 
The anti-MopB selected single chain antibody sequence (anti-MopB scFv) was 
digested with NcoI and NotI restriction enzymes and ligated into NcoI and NotI 
restiction sites of previously digested pSANG10-3F plasmid to make the pSANG-
MopB scFv plasmid. The pSANG10-3F plasmid carries an in-frame pelB signal 
peptide sequence. The fragment including the pelB leader and the MopB scFv (Figure 
2.5b) was ligated into the digested pBSKCA19.9 plasmid (Figure 2.5c) as a NdeI and 
NotI fragment and transformed into XL1-Blue competent cells. The plasmid was 
isolated and confirmed by DNA sequencing (section 2.7).  
 
The plasmid pBlueScriptII mCit (pBSKmCit) contains a constitutive promoter (lac 
promoter) to drive the expression of monomer fluorescent protein citrine. Pantoea 
agglomerans transformed with this vector were observed as green/yellow fluorescent 
bacteria.  The plasmid has suitable NdeI and HindIII insertion sites (Figure 2.5e) to 
accept the pelB signal peptide-MopB scFv-6xHis-tag encoding fragment (Figure 
2.5d) resulting in pARM4 plasmid. This expression cassette starts from a constitutive 
promoter with a pelB signal peptide sequence-MopB scFv-6xHis-tag to engineer 
Pantoea agglomerans to express selected recombinant antibody. The sequence was 




Figure 2.5 pARM4 plasmid construction. a) The MopB scFv was ligated into pSANG10-3F plasmid 
to construct pSANGMopBscFv plasmid. b) This plasmid was digested with NdeI/NotI to add pelB 
sequence to MopB scFv. c) This fragment was ligated into pBSKCA19.9 plasmid to construct 
pBSKCA19.9 pelB sequence- MopB scFv. d) This plasmid was digested with NdeI/HindIII to add 
6xHis-tag to the pelB sequence-MopB scFv. e) The pelB sequence- MopB scFv-6xHis fragment was 
ligated into pBSKmCit plasmid to add a constitutive promoter to the pelB sequence- MopB scFv-
6xHis fragment.  
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2.18.5  Anti-MopB scFv Expression and Detection in Pantoea agglomerans 	  
a.  Electro-Transformation  
 
Pantoea agglomerans was electro-transformed with 7 µL pARM4 plasmid using  
Bio-RAD electroporation as described in section 2.18.3. A transformation without the 
plasmid was also performed. In parallel, XL1-Blue cells were transformed (section 
2.7) with pARM4. The transformed cells were plated onto LB agar plates containing 
100 µg/mL of carbenicillin and grown overnight at 37 °C. 
 
Two colonies from each plate were used in colony PCR (section 2.8) and inoculated 
into 10 mL LB medium containing the same antibiotic and grown overnight at 37 °C. 
Purified plasmid from the XL1-Blue E. coli overnight culture was confirmed by 
sequencing (section 2.14.1). 
                                     
b.  Overnight anti-MopB scFv Expression and Purification  
 
Five colonies from Pantoea agglomerans and XL1-Blue cells transformed with 
pARM4 plasmid (section 2.18.5) were inoculated in to 50 mL LB medium containing 
100 µg/mL of carbenicillin and grown overnight at 37 °C. The cultures were allowed 
to reach the same OD600 absorbance of 1.3.  
 
The expression was checked using the following steps; first 1 mL of the overnight 
cultures were centrifuged at 13,000 g for 1 minute and kept as a cell pellet sample. 
Next, to check the presence of the anti-MopB scFv in the media ethanol precipitation 
method was performed. Briefly, the supernatant of 1 mL of overnight culture was 
mixed with 9 mL 100 % ethanol and kept at -20 °C at least for 1 hour. The 10 mL 
mixture was centrifuged at 14,000 g for 15 minutes and the supernatant was 
discarded and tubes dried by inversion. The cell pellet was washed with 10 mL 90 % 
cold ethanol and centrifuged at 14,000 g for 5 minutes. The cell pellet was air dried 
and kept as precipitated protein in the media.  
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The rest of the overnight cultures were centrifuged at 4000 g for 10 minutes and the 
cell pellets were used in periplasm (osmotic shock) protein purification as described 
in The QIAexpressionistTM -- A handbook for high-level expression and purification 
of 6xHis-tagged proteins, fifth edition with slight modification.  
 
The periplasmic fractions were collected by re-suspending the cell pellet in 3 mL of 
buffer PA (30 mM Tris base, 1 mM Ethylenediaminetetraacetic acid (EDTA),  
20 % sucrose pH 8.0) followed by 5 minutes incubation at 4 °C on ice. The bacterial 
cells were collected by centrifugation at 8000 g for 15 minutes at 4 °C; the 
supernatant (periplasmic fraction 1) was collected and stored on ice, while the cell 
pellet was re-suspended in 7 mL of 5 mM MgCl2. After incubating for 10 minutes on 
ice, the suspension was centrifuged at 8000 g for 15 minutes at 4 °C. The supernatant 
(periplasmic fraction 2) was collected and pooled with periplasmic fraction 1 (20 µL 
of both periplasmic fractions were stored on ice for further analysis). All the samples 
and the remaining cell pellets for periplamic purification (for the non-secreted 
recombinant protein expression) were analysed by SDS-PAGE as described in 
section 2.13.  
 
2.18.6  MopB scFv Protein Expression Analysis   
 
a.  SDS-PAGE 
 
The SDS-PAGE was performed as described in section 2.13.  
 
b.  Western Blot 
 
The Western blot was performed as described in section 2.17.5 using monoclonal 
anti- polyHistidine-alkaline phosphatase antibody (diluted 1/10,000 in 5 % 








































Chapter 3: Results 
 
3.1  Calibration of Bespoke Protein Marker 
 
In order to facilitate the detection and monitoring of protein size, especially in a 
Western blot probed by anti-His-tag antibody, His-tagged protein standards were 
prepared. Four known recombinant proteins [Thioredoxin TRX protein (20 kDa), 
RFP (30 kDa), MopB protein (42 kDa) and HSP 70 (75 kDa)] were fused to 6xHis-
tag and produced in E. coli, followed by affinity purification (section 2.14.3a). These 
His-tagged proteins were mixed for use as the markers in SDS-PAGE and Western 
blots, as described in section 2.5.5. A comparison of this bespoke protein marker and 
commercial protein marker is shown in Figure 3.1.  
 





Figure 3.1 Comparison of bespoke protein marker with Bio-Rad standards. Bespoke protein marker  
(5 µL) and Bio-Rad Precision plus protein dual Xtra standards (10 µL) were run on a 12% SDS-PAGE 
gel. a) The size comparison on SDS-PAGE stained by Coomassie blue; b) The comparison on Western 
blot, detected by monoclonal anti-polyHistidine-alkaline phosphatase antibody produced in mouse;  
c) The Bio-Rad Precision plus protein dual Xtra standards.  
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Furthermore, a size calibration graph was also plotted for both SDS-PAGE gels and 
Western blots results to show the correlation between two sets of protein markers (the 
size calibration graphs are presented in appendix 1.1, page 141). The comparison 
results for the bespoke protein marker and the Bio-Rad Precision plus protein dual 
Xtra standards reveals a good correlation between the observed sizes according to the 
SDS-PAGE gels and its related size calibration plot. However the observed sizes 
obtained from the Western blots and its related size calibration plot were slightly 
different. 
 
3.2  MopB Protein 
 
The aim of this project was to develop anti-Xylella proteins. According to previous 
studies (Fjellbirkeland et al., 2000, Bruening, 2003, Bruening, 2005, Morano et al., 
2008) and X. fastidiosa genomic information, an outer membrane protein (MopB) 
was chosen as a target to develop anti-Xylella MopB scFv antibodies. 
 
3.2.1  MopB Bioinformatic Analysis 
 
The X. fastidiosa Temecula 1 MopB protein sequence downloaded from NCBI data 
base  (NCBI Reference Sequence: NP_779898.1) was analyzed using SIG-PRED to 
predict the putative signal sequences (section 2.14.1). Accordingly, Met1-Ala36 
and/or possibly Met15-Ala36 were identified by the programme as putative signal 
sequences (Figure 3.2).   
 
   
 
Figure 3.2  The amino acid sequence of Xylella fastidiosa Temecula 1 MopB and the predicted model 
for the β-barrel outer membrane domain. The putative leader sequence starting at Met1 is indicated 
with black underlining; a shorter potential leader sequence starting at Met15 (previously identified by 
(Bruening, 2002) is indicated with a black line over the sequence and gray highlighting.  
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The SIG-PRED and PRED TMBB programmes (section 2.14.1) were used to predict 
the signal peptide cleavage site (Figure 3.2). The arrow between Ala36 and Gln37 
denotes signal peptide cleavage site, periplasmic regions (grey), membrane spanning 
regions (blue) and surface exposed loops (red). The yellow highlighted region 
corresponds to the truncated MopB (the surface exposed loops, which is the predicted 
antigenic part of the protein presented on the cell surface).  
 
Sequence scored a value of 2.929, which is lower than the threshold value of 2.965. 
The difference between the value and the threshold indicates the possibility of the 
protein being an outer membrane protein. The well characterised E. coli OmpA 
sequence analysed using PRED TMBB scored 2.861.   
 
The β-barrel trans-membrane domain identification using PRED TMBB (section 
2.14.1) was predicted to be between Trp43-Tyr177 using three methods: Viterbi 
algorithm (Rabiner, 1989), N-best methods (Krogh, 1997) and the posterior decoding 
method.  The Viterbi, N-best methods had an identical output in predicting the trans-
membrane regions and exposed loops.  The posterior decoding method differed 
slightly from the other two methods in its prediction of the final exposed loop amino 
acid 130-160 and a trans-membrane region 161-177 (as opposed to 130-164 and 165-
177 predicted by the Viterbi and N-best methods). A two dimensional representation 
of the Viterbi method show the exposed loops with the last loop being the longest 






Figure 3.3 A two-dimensional (2D) figure of the predicted MopB transmembrane β-barrel with the 
protruding surface exposed loops generated using PRED TMBB. The amino acid numbers of the 
beginning and end of the β-strand traversing the outer membrane are in green.  
 
3.2.2  Expression and Purification of the MopB Protein 
 
The gene encoding full length mature Met-Ala36-Asn389 (1084 bp) and a truncated 
(564 bp) Met-Ala36-Gly252 MopB (the surface exposed portion of MopB) from X. 
fastidiosa MopB were PCR amplified from pMALc2x_mopB plasmid as described in 




Figure 3.4 Gel electrophoresis for MopB PCR products using pMALc2x_mopB as a template. Lane 1, 
100 bp DNA ladder; Lane 2, blank; Lane 3, Truncated MopB PCR product with expected size of ~564 
bp; Lane 4, blank; Lane 5, full-length MopB PCR product with expected size of ~1084 bp; Lane 6, 
blank. 
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The amplified PCR products were cloned into the pSANG10-3F vector and were 
used to transform XL-Blue E. coli competent cells. The purified plasmids (Figure 











Figure 3.5 Plasmid map of MopB contructs in pSANG10-3F vector. a) Full length mature MopB;  





The plasmids were transformed into BL21(DE3) E. coli strain to express the cloned 
MopB proteins. Proteins analysis by SDS–PAGE revealed abundant full length 
mature and truncated MopB at 3 hours at 37 °C post induction with IPTG (section 
2.14.2).  
 
The recombinant full length mature and truncated MopB were expressed in 
pSANG10-3F vector as fusion with hexa-histidine followed by the Tri-FLAG tag.  
 
Expressed recombinant mature MopB was predicted to have a theoretical iso-electric 
point (pI) (Gasteiger et al., 2003) of 6.36 and a molecular weight (Mw) of 42.98 kDa. 
Expressed truncated form of recombinant MopB, the exposed loops, which is the 
predicted antigenic part of the protein presented on the cell surface, was predicted to 
have a pI of 6.79 and Mw of 24.64 kDa. 
 
The SDS–PAGE results indicated proteins with an apparent molecular weight of 
about 43 kDa for full length mature MopB and 25 kDa for truncated MopB (Figure 
3.6a and b). Using the method described in section 2.14.3a the recoveries of 
recombinant mature and truncated MopB proteins using denaturing conditions were 
estimated to be approximately 50 mg/mL of culture. 
 
Native non-denaturing conditions during protein purification (section 2.14.3b) failed 
to recover either of the recombinant proteins in the soluble fraction (Figure 3.6 c and 
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                  a)                                                               b) 
                        
 
                  c)                                                               d) 
                        
 
  
Figure 3.6 SDS-PAGE analysis of recombinant MopB proteins. a) Denaturing conditions full-length 
mature MopB expression and purification. Lane 1, EZ- RUN protein molecular weight marker; Lane 2, 
non induced; Lane 3, induced; Lane 4, final wash; Lanes 5-6, elutions 2-3. The expected size of full 
length mature MopB protein (42.98 kDa) is indicated by arrow. b) Denaturing conditions truncated 
MopB expression and purification. Lane 1, EZ- RUN protein molecular weight marker; Lane 2, 
induced; Lane 3, flow through; Lane 4, final wash; Lanes 5-6, elutions 2-3. The expected size of 
truncated MopB protein (24.64 kDa) is indicated by arrow. c) Native conditions full length mature 
MopB expression and purification. Lane 1, EZ- RUN protein molecular weight marker; Lane 2, non 
induced; Lane 3, induced; Lane 4, soluble fraction; Lane 5, flow through; Lanes 6 and 7 elutions 2 and 
3. d) Native conditions truncated MopB expression and purification. Lane 1, EZ- RUN protein 
molecular weight marker; Lane 2, non induced; Lane 3, induced; Lane 4, soluble fraction; Lane 5, 
flow through; Lanes 6 and 7 elutions 2 and 3. 
 
3.3  Mouse Immunization 
 
Whole heat-killed X. fastidiosa (section 2.14.5) was used to immunize 5 Balb/c mice 
at ProSci (Poway, CA USA). Initial immunization was followed by boosting at week 
4,  8 and 12. Two weeks after boosting the test bleeds were taken and used in Dot 
blot analysis. The mice were boosted again and underwent a splenectomy after three 
days. Each mouse spleen was placed immediately in 10 mL of TRIZOL for RNA 




3.3.1  Bacterial Dot Blot 
 
The immune sera from bleed 3 (section 2.14.6) were evaluated in a Dot blot assay 
against milk protein, whole intact E. coli and X. fastidiosa Temecula 1 strain (Figure 
3.7). Mouse sera 1, 2, 4 and 5 had clear antibody binding to X. fastidiosa at a dilution 
of 1/20,000 whereas mouse 3 sera did not. The antibody activity against  
E. coli was not observed and the activity against milk proteins was absent or very 
weak in mouse sera 2 and 4. 
                                     
 
 
Figure 3.7 Mouse immune sera evaluation by immuno-dot blot.  Immuno-dot blot screen with 
1/20,000 dilution of bleed 3 mouse 1-5 sera on 5 % milk protein control, or 5 µL of E. coli or  
X. fastidiosa spotted directly onto nitrocellulose strips and probed with rabbit anti-mouse alkaline 
phosphatase and developed with NBT/BCIP. 
 
3.3.2  Recombinant MopB ELISA 
 
An ELISA assay was performed using recombinant truncated MopB protein and 
immune sera (bleed 3) from mice immunized with whole heat-killed X. fastidious 
(section 2.14.7). The ELISA results indicated that 4 out of 5 mice produced 
antibodies that recognise the recombinant truncated MopB protein with little or no 
cross-reactivity with the control protein BSA (Figure 3.8). The study was carried out 
with immune mouse sera dilutions of 1/20,000 and a threshold value of ≥ 0.1 was 
used as the cut-off value for detection of mouse sera 1-5 binding to the recombinant 
truncated MopB protein.                                 
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Figure 3.8 Mouse immune sera evaluation by ELISA. Mouse 1-5 sera from bleed 3 diluted 1/20,000 in 
the ELISA on truncated MopB (10 µg/mL) and BSA (10 µg/mL), blank (all the buffers without the 
antigen), rabbit anti-mouse (1/20,000) + anti-rabbit alkaline phosphatase 1/40,000) and anti-rabbit 
alkaline phosphatase (1/40,000) without anti-mouse. A threshold value of ≥ 0.1 was used as the cut-off 
value for detection of mouse sera 1-5 binding to the recombinant truncated MopB protein.  
 
3.4  Mouse Immunoglobulin Library Assembly 
 
The mice spleens (n=5) previously immunized with whole heat-killed X. fastidiosa 
kept in TRIZOL were used to construct five individual mouse single chain antibody 
libraries (section 2.15) in the form of VL-Link-VH. 
 
Total RNA was isolated from each mouse spleen (n=5) and were used as the template 
to generate five required cDNA synthesis followed by PCR amplification of 
individual variable light chain (VL) and heavy chain (VH) using specific designed 
primers (Table 2.1). 
 
3.4.1  RNA Extraction and cDNA Synthesis 
 
The RNA isolation followed the instructions provided with the TRIZOL reagent and 
the final volume was 50 µL (section 2.15.1). The concentration and purity of RNA 
recovered from the mouse spleens (n=5) previously immunized with whole  
heat-killed X. fastidiosa is presented in Table 3.1.  
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Table 3.1 Total RNA extraction concentrations and A260/280 and A260/230 ratios obtained from 5 mice 
spleens previously immunized with whole heat-killed X. fastidiosa. 	  
 
 
The individual (n=5) total RNA samples obtained from five immunized mice spleens 
provided ample material for the subsequent five cDNA reactions (section 2.15.2). 
The Oligo-dT29VN primer was used to synthesis cDNA for light chains and 
MVHlink2 primer for heavy chains (all primers are listed in Table 2.1).  
 
3.4.2  Construction of Single-Chain Antibody Libraries 
 
Five immunoglobulin libraries were assembled individually using their corresponding 
cDNAs as outlined in the schematic (Figure 2.1) section 2.15.3.  
 
Oligo-dT29VN and MVHlink2 generated cDNAs were used as template with 
antibody family-specific primers to amplify individual PCR products of 7 variable 
light chains fragments (VL) and 10 variable heavy chain fragments (VH).  
 
The PCR amplification results and steps of the library construction performed using 
mouse 4 spleen derived cDNA are shown in figures 3.9 and 3.10. All 5 mice 
immunoglobulin libraries were assembled using the same procedure. 
 
Figure 3.9a and b present individual PCR products of seven light chain fragments 
(VL) and 10 heavy chain fragments (VH) amplified from mouse spleen 4. DNA 
bands with expected size of ~350 bp for VL and ~400 bp for VH (indicated by arrow) 
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  a) 
 
                                                
                                                        
  b) 
 
 
Figure 3.9 PCR products of 7 light chains and 10 heavy chains. a) PCR product of 7 light chains. Lane 
1, 100 bp ladder; Lane 2, Vκ1; Lane 3, Vκ2; Lane 4, Vκ3; Lane 5, Vκ4; Lane 6, Vκ5; Lane 7, Vκ6; 
Lane 8, Vκ7. The expected size of products (~350 bp) is indicated by arrow. b) PCR product of 10 
heavy chains. Lane 1, 100 bp ladder; Lane 2, VH1; Lane 3, VH2; Lane 4, VH3; Lane 5, VH4; Lane 6, 
VH5; Lane 7, VH6; Lane 8, VH7; Lane 9, VH8; Lane 10, VH9; Lane 11, VH10. The expected size of 
VH products (~400 bp) is indicated by arrow. 
 
 
In all five mice library constructions, mouse Vκ6, VH4 and 8 were amplified at lower 
levels; all other families were readily amplified. This amplification pattern for mouse 
variable light chains and heavy chains was likely due to the primer design. 
 
Variable light chains and heavy chains were assembled by adding linkers to both 
purified mixtures of VL and VH families separately generating a ~410 bp PCR 
product (Figure 3.10a); Then the VL-Link and VH-Link were assembled in the form 
of VL-Link-VH PCR product of ~750 bp (Figure 3.10b).  
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The Mouse Kappa Constant (MKC) was amplified using pUC57NPNAMKC plasmid 
(GenScript) as template, and MKNotCF and MKRev primers (Table 2.1). The 
expected size for MKC was ~310 bp (Figure 3.10c).  
 
The MKC was joined to the VL-Link-VH combinations by a PCR overlap extension 
reaction using MVKFlink and MKRev with expected size of ~1100 bp indicated by 
the arrow (Figure 3.10d).  
 
a)                                               b) 
 
 
                                                                                                         
            c)                                      d)                                           e) 
   
 
 
Figure 3.10 PCR products of mouse library construction. a) VL-Link & VH-Link, Lane 1, 100 bp 
ladder; Lane 2, VL-Link; Lane 3, VH-Link. The expected size of VL-Link and VH-Link products 
(~410 bp) is indicated by arrow. b) VL-Link-VH. Lane 1, 100 bp ladder; Lane 2, VL-Link-VH. The 
expected size of VL-Link-VH products (~750 bp) is indicated by arrow. c) Mouse Kappa Constant 
(MKC). Lane 1, 100 bp ladder; Lane 2, MKC 3.The expected size of MKC products (~350 bp) is 
indicated by arrow. d) VL-Link-VH-MKC. Lane 1, 100 bp ladder; Lane 2, VL-Link-VH-MKC; The 
expected size of VL-Link and VH-Link products (~1100 bp) is indicated by arrow. e) T7-VL-Link-
VH-MKC. Lane 1, 100 bp ladder; Lane 2, T7-VL-Link-VH-MKC. The expected size of T7-VL-Link-
VH-MKC products (~1100 bp) is indicated by arrow. 
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Finally, the T7 site was added to the PCR product encoding all the variable light 
chains, variable heavy chains and MKC combinations using primers RDT7 and 
MKRev to produce the DNA encoding the anti-X. fastidiosa immunoglobulin scFv 
libraries with expected size of ~1100 bp indicated by arrow (Figure 3.10e) (all 
primers are listed in Table 2.1). 
 
The final DNA template encoding the antibody library flanked by a T7 site and a 
synthetic mouse kappa constant (MKC) chain was used in an in vitro ribosome 
display (Figure 3.10e). 
 
	  3.5  In vitro Ribosome Display and Antibody Selection 
 
Monoclonal antibodies were traditionally produced using rodent immunization 
followed by hybridoma screening. Recently to generate high affinity, specific and 
stable monoclonal antibodies, display technologies are used (Kohler and Milstein, 
1975, He and Khan, 2005). 
 
In this project, specific antibodies were selected against recombinant MopB protein 
by the use of a powerful display technology, in vitro ribosome display (section 2.16).  
 
Five mice antibody libraries were assembled and extended at the 5’ with T7 site and 
in the 3’ end with a spacer (MKC) (Figure 3.10e) and were used individually in an in 
vitro ribosome display as described in section 2.16.  
 
The full-length antibody library (T7-VL-Link-VH-MKC) PCR products (about 1100 
bp) were added into TNT coupled reticulocyte lysate and the mixture were incubated 
at 30 °C for 90 minutes to generate (antibody-ribosome-mRNA) ARM complexes as 
described in section 1.10. The translation mixture was then added into wells coated 
with 10 µg/mL of recombinant truncated and full length MopB antigen for an 
additional one hour. After washing with 1X PBS, the bound ARM complexes on 
wells were directly subjected to one step®RT-PCR using MVKFlink and MKRD2 
primers as described in section 2.16 (All primers are listed in Table 2.1) to recover 
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the selected genetic information. Recovered PCR products of ~900 bp was analysed 
by agarose gel electrophoresis (Figure 3.11).  
                                           
 
Figure 3.11 PCR products of first round of ribosome display. The encoding antibody DNA after the 
first round of ribosome display was recovered using MVKFlink and MKRD2 primers. Lane 1, 100 bp 
ladder; Lane 2, PCR product after first round of ribosome display against BSA (negative control); 
Lane 3, PCR product after first round of ribosome display against truncated MopB. The expected size 
of the recovered encoding antibody PCR product was ~900 bp (shown arrowed) 
 
 
To select antibodies against recombinant MopB, one round of ribosome display was 
initially performed using the mouse libraries (n=5) individually. The affinity enriched 
mRNA was amplified by RT-PCR, TOPO cloned and transformed into XL1-Blue E. 
coli to screen for blue/white colonies on an X-gal plate.   
 
In this chapter, only results obtained from mouse 4 antibody library are presented. 
From approximately one hundred white colonies on the X-gal plate after the first 
round of in vitro ribosome display using mouse 4 antibody library, four colonies were 
randomly selected and used to prepare plasmids for sequencing.  
 
The four recovered antibody-encoding DNA sequences (4XfMopB1-4) provided 
from 4 random colonies are presented in appendix 1.3 (pages 144-147) 
[The nomenclature for numbering the scFv is as follows: mouse number (#1-5), 
bacterial strain antigen (X. fastidiosa), bait (MopB) and clone in order of isolation 
i.e.,]. DNA sequencing analysis results revealed that from 4 recovered encoding 
antibody sequences, three antibodies sequences were confirmed intact in-frame 
(4XfMopB1, 4XfMopB2 and 4XfMopB3). The 4XfMopB4 scFv antibody sequence 
showed a stop codon (tag) in the variable heavy chain.  
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The selected antibodies sequences (4XfMopB1, 4XfMopB2, 4XfMopB3 and 
4XfMopB4) were analysed at the IMGT website (Giudicelli et al., 2004). The 
variable region sequence analysis (Table 3.2) shows that different antibody gene 
segment sequences are present in the selected recombinant antibodies clones. The 
sequences were aligned with the online database and all of the Vκ and VH domains 
showed 99-100 % similarities to published mouse VL and VH domains(Altschul et 
al., 1990).  
 
Table 3.2 Junction analysis and alignment of the VL and VH CDR3 sequences of the selected anti-
MopB scFv’s (4XfMopB1-4). The sequences of the scFv’s were analysed using IMGT®, the 






3.6  MopB scFv Expression and Purification  
 
3.6.1  Analysis of MopB Antibody Expression and Solubility in E. coli 
 
The confirmed 4XfMopB1, 4XfMopB2 and 4XfMopB3 intact in-frame VL and VH 
combinations were sub-cloned into pAHAHis expression vector (incorporating a  
C-terminal peptide sequence HA tag (DVPDYAS) followed by a hexa-histidine-tag; 
this allowed for his-tagged antibodies to be purified for cytoplasmic protein 
expression in Rosetta gami B(DE3) E. coli and subsequent characterization) (section 
2.17). 
 
Rosetta gami B(DE3) strains were used due to their ability to enhance the disulfide 
bond formation and improve eukaryotic proteins expression in E. coli by carrying a 
plasmid for codons rarely used in E. coli. DNA sequencing results for selected MopB 
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antibodies (4XfMopB1-3) in pAHAHis expression vector are presented in  
appendix 1.4 (page 148). 
 
To determine whether or not the antibodies were expressed in the Rosetta gami 
B(DE3) E. coli strain, the expressed antibody fragments were first examined by 
purifying the scFvs by Ni2+-NTA column from total bacterial extracts under 
denaturing conditions with 8 M Urea as described in section 2.17.3a. The His-tagged 
scFv proteins were eluted from Ni2+-NTA columns by decreasing the pH from 8.0 to 
4.5. The eluted fractions were analysed by SDS-PAGE (Figure 3.12a). The SDS-
PAGE analysis revealed that dominant proteins with expected scFv size were 
isolated. To determine whether the antibodies were soluble and correctly folded, the 
expressed antibody fragments were purified from the total cell extract under native 
conditions as described in section 2.17.3b. Under native conditions, 8 M Urea was 
replaced by 500 mM NaCl and the pH was maintained at 8.0 in all buffers. The scFvs 
were eluted from the Ni2+-NTA column by increasing the imidazole concentration 
(Figure 3.12b).  
 
Analysis of the recombinant antibodies by SDS-PAGE show that they were 
successfully expressed and purified using Rosetta gami B(DE3) E. coli. Figure 3.12 
shows the SDS-PAGE gel for 4XfMopB3 scFv antibody (the SDS-PAGE gels for 
4XfMopB1 and 2 are not presented). Comparing the purified antibodies expected size 
(~27 kDa) upon IPTG induction with the non-induced (lane 2) and induced (lane 3) 
protein samples, revels the correct expected protein size. The scFv recovery under the 
denaturing condition shows large quantity of eluted proteins (Figure 3.12a; Lane 7, 8, 
9 and 10). However small amount of the scFv was eluted under the native condition 
(Figure 3.12b), which indicates that although recombinant scFv was expressed in a 
large quantity, but only a small fraction was soluble. The native condition 
purification also revels a number of contaminating co-purifying proteins, detected in 
the eluted samples (Figure 3.12b), which may reflect the inefficiency of immobilised 
metal ion affinity chromatography (IMAC) purification under the native condition.  
 
The presence of the successful selected scFv antibodies expression was confirmed by 
Western blot using soluble scFv proteins fractions and monoclonal anti-
polyHistidine-alkaline phosphatase antibody. A ~27 kDa protein of the expected size 
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of the expressed anti-MopB-scFv protein was observed by Western blotting (lane 3) 
and eluted fractions (lane 7-10) from total cell extract purification under the native 
condition. Figure 3.13 shows the Western blot result for anti-MopB scFv antibody 
4XfMopB3; Western blot results for 4XfMopB1 and 2 are not shown. 
 
 
                                 a) 
                              
 
                                
 





Figure 3.12 SDS-PAGE analysis of anti-MopB scFv antibody (4XfMopB3). a) MopB scFv antibody 
expression and purification under denaturing conditions. Lane 1, Bespoke protein marker; Lane 2, non 
induced; Lane 3, induced; Lane 4, soluble fraction, Lane 5, flow through; Lane 6, final wash;  
Lane 7-10, elutions 1-4. b) MopB scFv antibody expression and purification under native conditions. 
Lane 1, Bespoke protein marker; Lane 2, non induced; Lane 3, induced; Lane 4, soluble fraction; Lane 
5, flow through; Lanes 6, final wash; Lane 7-10 elutions 1-4. Immunoreactive bands of approximately 






Figure 3.13 Western blot analysis of anti-MopB scFv antibody (4XfMopB3) expression and 
purification (Native conditions). Lane 1, Bespoke protein marker, Lane 2, non induced, Lane 3, 
induced, Lane 4, soluble fraction, Lane 5, flow through, Lanes 6, final wash; Lane 7-10 elutions 1-4. 
Immunoreactive bands of approximately 27 kDa are indicated by the arrow.  
 
3.6.2  MopB scFv Functional Assays 
 
To examine antibody specificity and binding, the selected anti-MopB scFv antibodies 
(4XfMopB1-3) expressed in pAHAHis vector were tested first by Western blot. After 
confirming the binding to the recombinant MopB proteins on the Western blot the 
candidate scFvs were used in ELISA and Immunofluorescence assays against 
recombinant full length mature, truncated MopB and heat-killed X. fastidiosa. 
 
Binding of the scFv antibodies to recombinant MopB were detected via a peptide 
sequence derived from influenza hemagglutinin, HA tag (section 2.17.1). A 
secondary recombinant antibody was used where the anti-HA peptide scFv was fused 
to alkaline phosphatase (anti-HA scFv-phoAM) as described in section 2.17.1b. To 
confirm the MopB scFv binding, a non-specific antibody for MopB protein 2A10 
scFv (2A10 scFv antibody for NPNA malaria antigen) was expressed and purified as 
negative control (section 2.17.1a).  
 
The scFvs were expressed using pAHAHis plasmid and purified under native 
conditions (section 2.17.4). Analysis of the purified anti-HA-phoAM and 2A10 
purified scFv antibodies by SDS-PAGE are presented in Figures 3.14a and b for  
anti-HA-phoAM and 3.15a-c for 2A10 scFv. 
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Figure 3.14 SDS-PAGE analysis of anti-HA-phoAM scFv antibody expression and purification using 
pAHAHis plasmid. a) Denaturing conditions. Lane 1, Bespoke protein marker; Lane 2, non induced; 
Lane 3, induced; Lane 4, soluble fraction, Lane 5, flow through; Lane 6, final wash; Lane 7-10, 
elutions 1-4. b) Native conditions. Lane 1, Bespoke protein marker, Lane 2, non induced, Lane 3, 
induced, Lane 4, soluble fraction, Lane 5, flow through, Lanes 6, final wash; Lane 7-10 elutions 1-4. 





























Figure 3.15 SDS-PAGE and Western blot analysis of 2A10 scFv antibody expression and purification 
using pAHAHis plasmid. a) Denaturing conditions. Lane 1, Bespoke protein marker; Lane 2, non 
induced; Lane 3, induced; Lane 4, soluble fraction, Lane 5, flow through; Lane 6, final wash; Lane 7-
10, elutions 1-4. b) Native conditions. Lane 1, Bespoke protein marker, Lane 2, non induced, Lane 3, 
induced, Lane 4, soluble fraction, Lane 5, flow through, Lanes 6, final wash; Lane 7-10 elutions 1-4.  
c) Western blot analysis (Native conditions). Lane 1, Bespoke protein marker, Lane 2, non induced, 
Lane 3, induced, Lane 4, soluble fraction, Lane 5, flow through, Lanes 6, final wash; Lane 7-10 




a.  Western Blot 
 
Western blot analysis was performed to examine anti-MopB scFv antibodies 
(4XfMopB1-3) binding to the recombinant MopB proteins. Recombinant truncated 
and full length mature MopB proteins were transferred to PVDF membrane and 
purified diluted (1/10) anti-MopB scFv antibody elutions (primary antibody) were 
added to the membrane and incubated. To identify the antibody binding to the MopB 
proteins, the purified HA-phoAM scFv conjugate with alkaline phosphatase was 
added to the membrane (secondary antibody) and incubated. The HA-phoAM scFv 
detects the HA peptide fused to the purified anti-MopB scFv antibody. 
  
Western blot results showed that anti-MopB scFv 4XfMopB1 (result not shown) and 
4XfMopB3 detected recombinant full length mature and truncated MopB. Results for 




Figure 3.16 Functional Analysis of 4XfMopB3 HA scFv by Western blot. a) SDS-PAGE analysis of 
the mature full-length and truncated MopB proteins. Lane 1, truncated MopB; Lane 2, full-length 
mature MopB. b) Western blot using 4XfMopB3 HA scFv and HA-PhoAM scFv to detect full-length 
mature and truncated MopB on PVDF membrane. Lane 1, truncated MopB; Lane 2, full-length mature 
MopB. 
 
b.  ELISA 
 
To examine the antibody specificity and binding, the selected antibodies 4XfMopB1 
and 4XfMopB3 expressed in pAHAHis vector were tested in ELISA against 
recombinant full length mature and truncated MopB. The ELISA was performed on a 
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96-well Nunc plate, with milk and 2A10 scFv were used as the negative controls. The 
purified bacterially expressed anti-MopB antibody (diluted 1/10 elutions) was 
incubated in each well. The secondary antibody, the purified HA-phoAM scFv 
conjugate with alkaline phosphatase (diluted 1/10 elutions), was added and incubated. 
A threshold value of ≥ 0.1 was used as the cut-off value for detection of 4XfMopB3 
scFv antibody binding to mature full and truncated MopB proreins. After detection, 
the anti-MopB (4XfMopB3) scFv antibody showed binding activity to recombinant 
full length mature and truncated MopB in ELISA. Figure 3.17 shows the ELISA 




Figure 3.17 Functional analysis of 4XfMopB3 HA scFv by ELISA. The antibody was tested against 
5% milk protein, mature full-length and truncated MopB. 2A10 scFv expressed in pAHAHis control 
antibody NPNA repeat (against Asn-Ala-Asn-Pro repeat) was used as an irrelevant negative control 
scFv. The secondary conjugate without a first antibody, and substrate alone, were used as additional 
controls. A threshold value of ≥ 0.1 was used as the cut-off value for detection of 4XfMopB3 HA scFv 
binding to mature full and truncated MopB protiens. 
 
The ELISA results show that 4XfMopB3 scFv antibody binds to truncated and full 
length mature MopB, whereas 4XfMopB1 detected MopB in Western blots only 
(data not shown). The ELISA result for 4XfMopB3 agrees with the Western blot 
result, confirming the binding activity of 4XfMopB3 antibody in both assays.  
The 4XfMopB3 scFv was consequently used to image X. fasitidosa by 
immunofluorescence microscopy. 
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c.  Immunofluorescence Analysis 
 
The functionality of recombinant anti-MopB scFv (4XfMopB3) was tested by 
immunofluorescence (IF) as described in section 2.17.6c.  
 
In this assay, slides of heat-killed whole X. fasitidosa were individually probed with 
purified 6xHis-tag antibodies. One X. fasitidosa slide was probed with anti-MopB 
4XfMopB3 scFv antibody (specific antibody to X. fasitidosa MopB) as primary 
antibody followed by secondary anti-polyHistidine-FITC antibody.  
 
Another X. fasitidosa slide was probed with primary antibody 2A10 scFv (antibody 
for NPNA malaria antigen) as negative control, followed by secondary anti-
polyHistidine-FITC antibody.  
 
In addition, to check for non-specific binding of the anti-polyHistidine-FITC 
antibody to X. fasitidosa, this antibody was used as a primary antibody only on an 
individual heat-killed whole X. fasitidosa slide as a control (section 2.17.6c).  
 
The X. fasitidosa slide probed with 4XfMopB3 MopB scFv specific antibody was 
first viewed with bright-field microscopy and then with fluorescence microscopy.  
X. fasitidosa were green immunofluorescent stained with anti-polyHistidine-FITC 
antibody using fluorescence microscopy, confirming that 4XfMopB3 scFv antibody 
binds to X. fasitidosa surface exposed MopB protein (Figure 3.18A and B).  
 
Negative control slides with X. fasitidosa and 2A10 scFv antibody (antibody for 
NPNA malaria antigen) and X. fasitidosa with the anti-polyHistidine-FITC antibody 
only, were also viewed with both bright-field microscopy and fluorescence 
microscopy. On both slides, X. fasitidosa did not show any green immunofluorescent 
staining using fluorescence microscopy (Figure 3.18C-F), which indicate that there 
was no non-specific binding to X. fasitidosa of control antibody or FITC conjugate. 
               
 
                                                                                                           













                   
 
 








Figure 3.18 Immunofluorescence detection of X. fastidiosa with 4XfMopB3 scFv. Panels A, C and E 
were viewed with bright-field microscopy and B, D and F with fluorescence microscopy. X. fastidiosa 
was probed with: A and B anti-MopB (4XfMopB3) HA scFv and secondary anti-polyHistidine-FITC; 
C and D 2A10HA scFv and secondary anti-polyHistidine-FITC (negative control); E and F probed 
with primary anti-polyHistidine-FITC only (negative control). The size bar shown in panels A and B 
are 5 µm. 
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3.7  Pantoea agglomerans  
 
Pantoea agglomerans (P. agglomerans), a member of the Enterobacteriaceae family, 
has been isolated from plants and insects. This bacterium is one of the important 
paratransgenic candidate species for controlling diseases such as Pierce's Disease 
(PD). 
 
In this study, P. agglomerans was engineered to express selected recombinant 
antibody for paratransgenesis control of PD. Therefore an expression cassette was 
designed for P. agglomerans to express and secrete the selected anti-MopB 
4XfMopB3 scFv antibody. 
 
The MopB scFv antibody expression cassette (section 2.18.4) for P. agglomerans is 
presented in figure 2.5.  This expression cassette contains a constitutive promoter (lac 
promoter) from pBSKmCit plasmid, pelB sequence from pSANG10-3F plasmid and 
6xHis-tag from pBSKCA19.9 plasmid. The anti-MopB 4XfMopB3 scFv antibody-
encoding gene was cloned into the NcoI/ NotI sites between the pelB sequence and 
6xHis-tag. 
 
To check for a suitable plasmid for P. agglomerans with a constitutive promoter, a 
pBlueScriptII mCit (pBSKmCit) plasmid was used. The pBSKmCit plasmid contains 
a constitutive promoter to drive the expression of monomeric fluorescent protein 
citrine. This plasmid was used to transform P. agglomerans and as the result 
green/yellow fluorescent bacteria were observed (Figure 3.20).   
 
The pBSKmCit plasmid has suitable NdeI and HindIII insertion sites (Figure 2.5d) to 
accept the pelB signal peptide sequence-MopB scFv-6xHis-tag encoding fragment 
(Figure 2.5e) resulting in pARM4 plasmid. This expression cassette starts from the 
constitutive promoter with a pelB signal peptide sequence-anti-MopB scFv 
4XfMopB3-6xHis-tag to engineer P. agglomerans to express selected recombinant 
antibody. The pARM4 plasmid sequence was confirmed by DNA sequencing (section 
2.14.1). The pARM4 plasmid sequence is presented in appendix 1.5 (page 149). 
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3.7.1 Pantoea agglomerans Antibiotic Susceptibility (Antibiogram) 
 
In order to find a compatible plasmid vector for P. agglomerans, it was necessary to 
identify a suitable antibiotic resistance marker to select the cells. To determine the 
antibiotic susceptibility of P. agglomerans, the disc diffusion (Kirby–Bauer) 
technique was performed.  
 
P. agglomerans were subjected to 4 common, antibiotics (Tetracycline, Ampicillin, 
Neomycin and Chloramphenicol) on LB agar plates (Figure 3.19). The results 
presented in Table 3.3 and Figure 3.19 show that P. agglomerans was sensitive to all 
antibiotics.  
 
                                         
 
Figure 3.19 Pantoea agglomerans antibiogram plate. Growth inhibition around antibiotic-impregnated 
disks indicates sensitivity of the bacterium to these antibiotics. Pantoea agglomerans was sensitive to 
all antibiotics (Tetracycline > Ampicillin> Neomycin > Chloramphenicol). 
 
Table 3.3  Pantoea agglomerans antibiogram zones of inhibition. 
 
Antibiotics Disc potency Diameter of zone of inhibition (cm) 
Tetracycline 50µg 1.5 
Ampicillin 10µg 0.7 
Neomycin 10µg 0.4 
Chloramphenicol 50µg 0.1 
 
 
According to the Pantoea agglomerans antibiogram zones of inhibition, ampicillin 
was chosen as the selection marker. However, in this study ampicillin was replaced 
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with an analogue antibiotic, carbenicillin, due to its lower sensitivity to low pH and 
greater stability.  For this reason Pantoea agglomerans was transformed with a 
plasmid containing carbenicillin resistance. 
 
Figure 3.20 shows the electro-transformed P. agglomerans fluorescence colonies 
under UV with pBSKmCit plasmid containing a constitutive promoter to drive the 





Figure 3.20	   Electro-transformation of P. agglomerans with pBSKmCit plasmid. P. agglomerans 
fluorescence colonies under UV on LB agar plates containing 100 µg/mL of carbenicillin.  
 
 
 3.7.2  Electro-Transformation of Pantoea agglomerans with pARM4 Plasmid 
 
To express the anti-MopB scFv antibody in Pantoea agglomerans, the pARM4 
plasmid containing the expression cassette (constitutive promoter-pelB signal peptide 
sequence-anti-MopB scFv (4XfMopB3)-6xHis-tag) was electro-transformed into  
P. agglomerans as described in section 2.18.5a. Figure 3.21 shows the successful 
transformation of P. agglomerans with the pARM4 plasmid on LB agar plates 
containing 100 µg/mL of carbenicillin. 
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Figure 3.21 Electro-transformation of Pantoea agglomerans with pARM4 plasmid. P. agglomerans 
colonies on LB agar plates containing 100 µg/mL of carbenicillin. a) P. agglomerans with pARM4. b) 
P. agglomerans without the plasmid (control).  
 
Colony PCR was performed to confirm the presence of the plasmid in the 
transformed P. agglomerans (Figure 3.22) (all primers are listed in Table 2.1). The 
DNA sequencing result for pARM4 plasmid with 4XfMopB3 anti-MopB antibody 





Figure 3.22 Colony PCR results of P. agglomerans with the pARM4 plasmid. Lane 1, 100 bp ladder; 
Lane 2, PCR product of MopB scFv using MVKF1 & MVHR1.1 primers; Lane 3, PCR product using 
pUC M13F & MVHR1.1 primers. Lane 4, PCR product using MVKF1 & pUC M13R primers.  
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3.7.3  Expression and Secretion of anti-MopB 4XfMopB3 scFv in P. agglomerans 
 
The pARM4 vector with the constitutive promoter followed by pelB sequence anti-
MopB scFv (4XfMopB3) and 6xHis-tag was overnight expressed (section 2.18.5b) in 
both P. agglomerans and E. coli. The Western blot analysis for anti-MopB scFv 
secretion showed that the anti-MopB scFv was expressed in P. agglomerans but not 
secreted, while the results for E. coli showed that the anti-MopB scFv was expressed 
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Figure 3.23 SDS-PAGE and Western blot analysis of anti-MopB (4XfMopB3) scFv overnight 
expression and detection in E. coli using pARM4 plasmid. a) SDS-PAGE. Lane 1, Bespoke protein 
marker; Lane 2, cell pellet; Lane 3, cell pellet after periplasmic purification; Lane 4, media ethanol 
precipitate, Lane 5, perplasmic fraction 1; Lane 6, perplasmic fraction 2; Lane 7, perplasmic fractions 
1 and 2; Lane 8, blank. b) Western blot. Lane 1, Bespoke protein marker; Lane 2, cell pellet; Lane 3, 
cell pellet after periplasmic purification; Lane 4, media ethanol precipitate, Lane 5, perplasmic fraction 
1; Lane 6, perplasmic fraction 2; Lane 7, perplasmic fractions 1 and 2, Lane 8, blank. The arrows 
indicate the expressed and secreted scFv (4XfMopB3) in E. coli with the predicted size of ~27kDa for 
the immunoreactive bands (lanes 2 and 4). 
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Figure 3.24 SDS-PAGE and Western blot analysis of anti-MopB (4XfMopB3) scFv overnight 
expression and detection in P. agglomerans using pARM4 plasmid. a) SDS-PAGE. Lane 1, Bespoke 
protein marker; Lane 2, cell pellet; Lane 3, cell pellet after periplasmic purification; Lane 4, media 
ethanol precipitate, Lane 5, perplasmic fraction 1; Lane 6, perplasmic fraction 2; Lane 7, perplasmic 
fractions 1 and 2; Lane 8, blank. b) Western blot. Lane 1, Bespoke protein marker; Lane 2, cell pellet; 
Lane 3, cell pellet after periplasmic purification; Lane 4, media ethanol precipitate, Lane 5, perplasmic 
fraction 1; Lane 6, perplasmic fraction 2; Lane 7, perplasmic fractions 1 and 2, Lane 8, blank. The 
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Chapter 4: Discussion 	  
An emerging problem for the grape industry in California is Pierce’s Disease (PD). A 
Gram negative xylem limited bacterium Xylella fastidiosa (X. fastidiosa) is the 
causative agent of PD (Davis et al., 1978). This is a vector-borne disease, in which 
xylem-feeding insects such as glassy-winged sharpshooter (GWSS) transmit  
X. fastidiosa from infected plants to others. These insects pick up the bacterium from 
the infected plants while they are feeding on them (Backus et al., 2009, Morano et 
al., 2008, Ramirez et al., 2008, Myers et al., 2007). X. fastidiosa attaches itself to the 
buccal cavity in the foregut of the xylem sap-sucking insect and the insects transmit 
the bacterium from one plant to another (Myers et al., 2007, Ramirez et al., 2008, 
Jackson et al., 2008). From the site of inoculation, X. fastidiosa multiplies and 
spreads to colonize the xylem, blocking the water transport network, causing scorch- 
like symptoms. One approach to control PD is to suppress transmission of the GWSS 
insect vector. Understanding the plant–pathogen–insect interface and molecular 
interactions may provide important information to prevent or reduce pathogen 
transmission. 
 
Release of the X. fastidiosa genome sequence (Simpson et al., 2000) facilitated the 
study of the surface proteins of X. fastidiosa, which may provide targets for 
intervention of Pierce’s Disease. MopB is an outer membrane protein, which has 
been identified on the coat surface of X. fastidiosa (Fjellbirkeland et al., 2000, 
Morano et al., 2008). The role of this protein (MopB) is not known, but it is well 
established that, in Gram negative bacteria, outer membrane proteins (OMPs) play 
important roles such as: 1) maintaining structural integrity of the outer membrane 
(OM), 2) transportation 3) membrane pores, 4) recognition proteins, 5) membrane 
bound enzymes or components of signal cascades (Bishop, 2008, Koebnik et al., 
2000, Kostakioti et al., 2005, Chen et al., 2010), 6) resistance to stressful conditions 
(OprF in Pseudomonas aeruginosa and OmpA in Escherichia coli are implicated in 
this role) (Gotoh et al., 1989, Woodruff and Hancock, 1989, Wang, 2002),  
7) pathogenesis (for instance, OspC in Borrelia burgdorferi and OmpA in 
Escherichia coli) (Khan et al., 2003, Prasadarao et al., 1996, Chen et al., 2010), and 
8) agglutination.  
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The aim of this project was to generate recombinant antibodies to investigate the 
interaction of MopB with the plant and GWSS. Towards this goal, recombinant 
MopB has been produced. Mice spleens (n=5) previously immunized with whole 
heat-killed X. fastidiosa were used to construct five mouse DNA libraries.  These 
libraries were used to generate MopB specific recombinant scFv antibodies by 
exploiting in vitro ribosome display technology. The selected recombinant scFvs 
were characterized by Western blot, Enzyme-Linked Immunosorbent assay (ELISA) 
and Immunofluorescence assay (IFA) analysis of recombinant MopB proteins and 
heat-killed X. fastidiosa.  
 
Furthermore, to prevent PD in the insect or plant, Pantoea agglomerans, a 
partrangenenic candidate, has been engineered to express selected recombinant 
antibodies against MopB protein. 
 
4.1  Surface Exposed Protein, MopB  
 
The X. fastidiosa genome sequence has provided valuable information about genes, 
metabolic pathways and potential virulence factors that may be involved in 
pathogenicity (Simpson et al., 2000).  
 
The X. fastidiosa genome sequence has been annotated, analysed and compared with 
other species genomes (Simpson et al., 2000, Van Sluys et al., 2003). X. fastidiosa is 
closely related to various Xanthomonas species (a Gram negative bacterium that 
colonizes the plant xylem). Genomic comparison analysis revealed similarities and 
differences between X. fastidiosa and Xanthomonas species. The Xanthomonad 
pathogen genome has been widely investigated and many genes have been implicated 
in the virulence of Xanthomonas species. Likewise, many of these homologous 
sequences are present in X. fastidiosa (Simpson et al., 2000, Hopkins and Purcell, 
2002, Chatterjee et al., 2008). According to this information it is possible to predict 
components that may have key roles in bacterial virulence and bacterial attachment to 
both plant and insect hosts.  
 
The outer membrane protein (MopB) has been studied in Xanthomonas. Chen et 
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al.,(2010) reported that mutation in Xanthomonas MopB (outer membrane protein) 
encoding gene results in: 1) changes in cell surface construction, 2) cell aggregation 
formation, 3) reductions in adhesion, motility and EPS xanthan gum productivity and 
4) sensitivity to stress conditions and loss of pathogenicity (Chen et al., 2010).  
 
A putative surface exposed molecule MopB (Fjellbirkeland et al., 2000, Morano et 
al., 2008) was selected from the completed genome sequence of X. fastidiosa 
Temecula1. The selected MopB protein sequence comparison indicated that the 
sequence was closely related to other X. fastidiosa strains and to Xanthomonas strains 
(about 96% identity). The sequence analysis showed the X. fastidiosa and 
Xanthomonas strain MopB proteins belong to the OmpA family.  
 
MopB protein is an appropriate target, because: 1) MopB is the most abundant 
protein in membrane preparations, 2) the sequence of MopB was identical in all X. 
fastidiosa subspecies and 3) MopB is accessible on the surface of X. fastidiosa 
(Dandekar et al., 2012). An in silico analysis of the target identified key features that 
assisted in the design of an appropriate recombinant bait molecule for use in antibody 
selection	   (section 2.14.1). X. fastidiosa MopB has a characteristic signal leader 
sequence Met15-Ala36 with a classical cleavage motif Ala Ser Ala, followed by a 
transmembrane β-barrel (with surface exposed loops) Trp43-Tyr177 and a 
periplasmic domain Arg178-Asn389 as described earlier in section 3.2.1.  
 
4.2  MopB Protein Expression in E. coli 	  
MopB is an outer membrane protein belonging to OmpA family (Fjellbirkeland et al., 
2000, Morano et al., 2008). In previous attempts to express recombinant MopB 
protein, the protein was inserted into the outer membrane using its natural leader 
sequence or an alternative such as ompA, which may be toxic to E. coli and resulted 
in limited success (Bruening, 2003, Bruening, 2005). A leaderless construct results in 
proteins not traversing or inserting into the inner membrane but being retained and 
aggregated in the bacterial cytoplasm due to the hydrophobic nature of the 




In this project, leaderless MopB gene constructs, cloned into the pSANG10-3F 
expression vector (Martin et al., 2006) result in proteins not traversing or inserting in 
the inner membrane but being retained in the bacterial cytoplasm and aggregated due 
to the hydrophobic nature of the transmembrane β-sheets (section 2.14).  
 
SDS-PAGE analysis showed that the leaderless full length mature (42.97 kDa) and 
truncated MopB (25.65 kDa) recombinant proteins were both efficiently expressed 
with the expected size. Extraction using denaturing conditions released the 
recombinant MopB protein into the soluble fraction. SDS-PAGE analysis tracking the 
expression and purification revealed that the recombinant proteins were enriched and 
the major products eluting from the affinity resin corresponded to the predicted sizes 
for the mature and truncated forms of the MopB protein, with yield of  
~50 mg/L of bacterial culture (section 3.2.2).    
 
Attempts to extract the proteins under native conditions using bacterial pellets from 
liquid cultures were unsuccessful, despite proteins of the predicted size being present 
in the induced cultures. The inability to release the recombinant MopB using the 
milder purification conditions (native conditions without 8 M urea) may be due to 
protein aggregation due to hydrophobicity of the β-barrel domain and or the 
formation of insoluble inclusion bodies.  
 
Using 6 M guanidine hydrochloride and 8 M urea in denaturing purification condition 
facilitated the solubilisation of the recombinant protein and permitted subsequent 
affinity enrichment, and the major product eluting for the affinity resin with the 
expected size. To remove the urea from the protein samples different methods such as 
dialysis (specially step-wise dialysis), buffer-exchange by gel filtration and dilution 
(Tsumoto et al., 2003) can be used. Attempts to remove the urea by buffer exchange 
using Sephadex G25 PD 10 column resulted in on column protein aggregation (data 
not shown), thus a dilution method was performed. The soluble truncated MopB 
protein was diluted in PBS to reduce the urea concentration and permit the protein to 
be immobilized on microtitre plate wells to determine whether immune sera raised 
against whole heat-killed X. fastidiosa would recognize elements of the 
transmembrane β-barrel component of MopB.  
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4.3  Mouse Immunoglobulin Library Assembly  
 
The ELISA results for recombinant truncated MopB protein and five mice immune 
sera previously immunized with whole heat-killed X. fastidious (section 3.3.2) 
revealed the presence of antibodies against the recombinant MopB protein. Five 
antibody libraries were assembled using the corresponding immune mice spleens in 
Trizol. The immune mice spleens were used to extract total RNA for 1st strand cDNA 
synthesis. These cDNA templates were used for PCR amplification of variable light 
and heavy chain families to construct five individual mouse immunoglobulin 
libraries. 
 
A set of degenerate primers was designed in this project to construct mouse 
immunoglobulin libraries. Using degenerate primers facilitates the diversity of the 
amplified product and introduces a complex pool of many oligonucleotide primers to 
achieve all possible rearranged variable regions.  
 
Based on information in the murine variable gene databases, 5’ primers were 
designed to amplify mouse variable light chain (VL) and heavy chain (VH), as 
described by Kettleborough et al., (1993). This set of primers enables recognition of 
all functional mouse variable genes. The degenerate 5’ primers for the variable light 
chain integrated an NcoI restriction site and the 3’ primers were designed to anneal at 
the end of the light chains to use elbow between VL and serine-glycine linker to join 
to the N-terminus linker of heavy chains. The 3’ primers for heavy chain application 
annealed at the end of gamma chain. This primer incorporated a NotI restriction site 
and as these DNA antibody libraries were used in the subsequent selection procedure 
(in vitro ribosome display) the primer was also designed to remove the stop codon 
from the DNA library as described earlier in section 1.10. 
 
Five individual mouse antibody libraries were assembled following the steps outlined 
in figure 2.1 by PCR to contain 7 variable light chain families and 10 variable heavy 
chain families. The gel electrophoresis analysis for variable light and heavy chains 
revealed that the mouse Vκ6, VH4 and 8 were present at lower levels of 
amplification while all other families were readily amplified. Light chains and heavy 
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chains were combined in the form of VL-Link-VH by linking each VL and VH 
fragment separately.  
 
In order to use the antibody DNA library in an in vitro ribosome display without 
requiring a cloning step, a T7 promoter and Kozak sequence were introduced 
upstream of the VL-Link-VH construct to allow the protein synthesis in an in vitro 
rabbit reticulocyte lysate as described in section 3.4.2.  
 
4.4  In vitro Ribosome Display 	  
Five individual mouse DNA libraries were constructed in the form of T7-VL-Link-
VH-MKC and used in an in vitro ribosome display to select specific functional 
antibodies against MopB protein. 
 
In vitro ribosome display is fully in vitro cell free technology for synthesising, 
screening and selecting polypeptides from large libraries. This technology, which is 
based on coupling the phenotype (protein) and genotype (genetic information DNA 
or RNA), is an alternative method to other display methods as described in section 
1.10 (Hanes and Pluckthun, 1997, He and Taussig, 2002, He and Khan, 2005).  
 
The advantage of in vitro ribosome display over other display technology methods 
(section 1.10) such as cell based systems (phage display (Winter et al., 1994)) are: 1) 
a large library can be displayed without bacterial transformation limitations; 2) toxic, 
proteolytical sensitive and unstable proteins can be generated using this technology 
(He and Khan, 2005, He and Taussig, 2002).  
 
The principal of this technology is based on in vitro transcription and translation of 
DNA library encoding open reading frames that lack stop codons at the 3ʹ′ ends. Due 
to the absence of the stop codon the ribosome will remain on the mRNA encoding 
protein to retain the genotype and phenotype, forming stable protein-ribosome-
mRNA (PRM) complexes. These complexes are used for affinity selection by 
immobilized target or ligand. The retained complexes, after removal of the 
 111	  
unbounded ones, will be reverse transcribed to cDNA and PCR amplified (He and 
Taussig, 2002, He and Khan, 2005, Douthwaite et al., 2006). 
 
Five mice DNA libraries encoding antibodies were individually used in the selection 
procedure. The in vitro ribosome display steps (He and Taussig, 2007) were 
optimized to facilitate the selection of affinity antibodies against the MopB protein.  
 
After a first round of selection (a single enrichment step) using recombinant truncated 
MopB as bait and mouse 4 DNA library in an in vitro ribosome display, single chain 
antibodies against MopB were selected and isolated (section 3.5). Only a single round 
of selection was performed due to using antibody libraries constructed from 
intentionally immunized sources, which may be a common feature of	   this rapid 
enrichment. 	  
 
DNA sequencing results for the four randomly selected anti-MopB scFv antibodies 
(4XfMopB1-4) (Appendix 1.3, pages 144-147), confirmed three intact in-frame VL-
VH combination antibodies (4XfMopB1-3). These antibodies (4XfMopB1-3) were 
analysed using the BLAST network service at the National Center for Biotechnology 
Information (NCBI, http:// www.ncbi.nlm.nih.gov), which indicated similarity to 
immunoglobulin superfamilies. BLASTX (for putative amino acid sequence) were 
used for sequence similarity searches for the light chains and the heavy chains. The 
sequence comparisons indicated that the 4XfMopB1, 4XfMopB2, 4XfMopB3 light 
chains were 96%, 98% and 97% identical respectively to immunoglobulin light chain 
variable region [Mus musculus]; and 4XfMopB1, 4XfMopB2, 4XfMopB3 heavy 
chains showed 99%, 98% and 100% identity respectively to immunoglobulin µ heavy 
chain variable regions [Mus musculus] (Altschul et al., 1990) .  
 
Furthermore, the sequences of the scFv’s were analysed using the International 
ImMunoGeneTics (IMGT®) information system® (Li et al., 2007, Zhang et al., 2011) 
to assign the mouse variable genes and alleles. For each isolated scFv (4XfMopB1-3) 
the light chain variable kappa region (Vκ), variable J region (VκJ) and 
complementarity determining region 3 (VL CDR3) and for the heavy chain variable 
region (VH), variable J region (VHJ), variable D segment (VHD) and 
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complementarity determining region 3 (VH CDR3) were analysed (Table 3.2). 
Analysis of the variable region sequences showed that different gene segments of the 
antibody sequences were present in the selected recombinant antibody clones.  
  
4.5  Anti-MopB scFv Expression in E. coli 	  
	  
After the first round of ribosome display using mouse 4 DNA antibody library, four 
randomly selected anti-MopB scFv antibodies (4XfMopB1-4) were sequenced 
(Appendix 1.3). Three of the four confirmed intact in-frame anti-MopB antibodies 
(4XfMopB1-3) were digested with NcoI and NotI and sub-cloned into pAHAHis 
expression vector for scFv expression in the Rosetta gami B(DE3) E. coli cytoplasm 
to overcome the expression of rare codons in E. coli (Novy et al., 2001). The 
pAHAHis plasmid was designed to add a C-terminal 6xHis-tag to the antibody to 
facilitate both purification and detection of expressed anti-MopB antibodies by 
Western blot using monoclonal anti-polyHistidine-alkaline phosphatase antibody 
(section 2.17). 
 
Rosetta gami B(DE3) is DE3 lysogen for λ prophage, which contains a chromosomal 
copy of an IPTG inducible T7 RNA polymerase under lacUV5 promoter control as 
described earlier in section 1.11.2a and b (Novy et al., 2001). This strain facilitates 
the eukaryotic protein expression by carrying a plasmid, which provides the tRNA for 
the codons (AUA, AGG, AGA, CUA, CCC, GGA) rarely used in E. coli (Novy et al., 
2001) and enables the disulfide bond formation of the target protein in the bacterial 
cytoplasm (Bessette et al., 1999, Prinz et al., 1997, Ritz and Beckwith, 2001).  
 
The anti-MopB scFv antibodies were expressed by using a routine antibody 
production method. The standard condition for antibody (protein) expression was set 
at 20 °C for 20 hours to reduce the cellular protein concentration and improve protein 
folding.  
 
The expression of the anti-MopB scFv’s was confirmed by purifying the expressed 
anti-MopB scFv’s from the cytoplasm under denaturing condition using a Ni2+-NTA 
column. The presence of 6 M guanidine hydrochloride and 8 M urea solubilised the 
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anti-MopB scFv’s recombinant protein and allowed subsequent affinity enrichment 
using affinity resin. Protein gel electrophoresis analysis revealed that the recombinant 
anti-MopB scFv’s were expressed, enriched and eluted with the expected size of  
~27 kDa for selected antibodies. After confirming the expression of the anti-MopB 
scFv antibodies in the Rosetta gami B(DE3) E. coli strain, it was necessary to purify 
soluble anti-MopB antibodies from the cytoplasm under the native condition to 
preserve antibody activity, increase the likelihood of correct folding and being 
functional.  
 
SDS-PAGE gel and Western blot results for purified 4XfMopB1-3 antibodies under 
native condition showed that the anti-MopB antibodies were purified with the 
expected size of ~27 kDa. However, this gel also showed contaminating proteins in 
the fractions.  
 
The presence of the contaminating proteins could be related to the inefficiency of 
immobilised metal ion affinity chromatography (IMAC) purification under the native 
condition. To eliminate the contaminated proteins, different concentrations of 
imidazole could be tested in the wash buffer followed by a few more washes. The 
purified anti-MopB scFvs from the cytoplasm under native conditions could be used 
directly for functional analysis.  
  
4.6  Anti-MopB scFv Functional Analysis 	  
The expressed selected anti-MopB scFv antibodies using pAHAHis expression vector 
(as described earlier in section 4.6 and 2.17.1) were tested for their functional 
properties against MopB protein using Western bolt, ELISA and 
Immunofluorescence Assay (IFA).  
 
In the pAHAHis vector, the C-terminal HA peptide (section 2.17.1) was designed to 
facilitate the detection of scFv and antigen binding. To detect the HA peptide, a 
secondary recombinant scFv antibody (anti-HA-phoAM scFv) against HA peptide 
was expressed, purified (section 3.6.2) and used in Western blot and ELISA. 
Moreover, a C-terminal 6xHis-tag was added to this construct to facilitate both 
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purification and detection of anti-MopB antibodies by IFA using anti-polyHistidine-
FITC antibody. 
 
Western bolt results show that of three selected anti-MopB scFv (4XfMopB1-3) 
antibodies two (4XfMopB1 and 4XfMopB3) recognized the recombinant truncated 
and mature full length MopB protein.  
 
The 4XfMopB3 anti-MopB scFv antibody was used in ELISA assays. The ELISA 
results indicated binding of the 4XfMopB3 antibody to both the recombinant 
truncated and mature full length MopB proteins. Although the signals are not strong 
in comparison with the negative controls they do however demonstrate binding.  
 
The weak binding signal could possibly be due to several reasons, including the low 
concentration of the recombinant scFvs (4XfMopB3 and HA-phoAM) used in the 
assay, using a recombinant scFv (HA-phoAM) to detect the binding of anti-MopB 
scFv with the recombinant MopB proteins. Despite the low binding, the ELISA result 
agrees with the Western blot results confirming the binding activity of 4XfMopB3 
antibody. 
  
Immunofluorescence assays (section 3.6.2c) demonstrated binding of the selected 
anti-MopB scFv (4XfMopB3) to the X. fasitidosa surface exposed MopB protein. The 
binding was specific sience the negative controls [X. fastidiosa probed with 2A10 
scFv antibody for NPNA malaria antigen (a non-specific scFv antibody for MopB 
protein) followed by the secondary anti-polyHistidine-FITC antibody and for X. 
fastidiosa with the anti-polyHistidine-FITC antibodies only] did not fluoresce. This 
results show that there was no non-specific binding between X. fastidiosa and the 
controls. 
 
Of the four selected scFv’s antibodies (4XfMopB1-4), one recognized the mature full 
length and truncated recombinant MopB proteins in both the Western blot and 
ELISA, and heat-killed X. fastidiosa by IF, suggesting that the epitope is 
nonconformational and possibly one of the three predicted loops exposed on the 
surface of the bacteria. The results of this study not only indicate the successful 
selection of functional scFv antibodies from mouse spleens previously immunized 
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with whole heat-killed X. fastidiosa by in vitro ribosome display technology, but also 
show the binding and interaction of the selected anti-MopB scFv (4XfMopB3) with 
the recombinant MopB proteins and the X. fastidiosa surface protein. The anti-MopB 
scFv (4XfMopB3) may also have a great potential in basic research and for easy, 
rapid, sensitive and specific early diagnosis of infected grapevines. Moreover, these 
results provide evidence that immunization with whole heat-killed X. fastidiosa 
clearly induces antibodies against surface exposed antigenic molecules such as 
MopB, indicating that the mild heat treatment used to kill the bacteria preserved the 
surface accessible protein immunogenicity. 
 
4.7  Engineered Pantoea agglomerans 	  
New control strategies are required for successful control and prevention of vector- 
borne diseases. One strategy is paratransgenesis, a novel strategy that use genetically 
modified insect symbionts to express molecules within the vector, which blocks the 
pathogen development or vector transmission. The aim of this strategy is to reduce 
the insect vectorial capacity and block the pathogen in the insect gut as described 
earlier insection 1.7.1 (Coutinho-Abreu et al., 2010). 
 
Advantages of paratransgenesis over the direct transgenic approach are: 1) bacterial 
genetic manipulation is much easier; 2) bacteria can be made to secrete or carry very 
specific agents such as single chain antibodies. This strategy has a wide application in 
disrupting vector-borne infectious diseases such as Chagas’ disease (Beard et al., 
2001), and also HIV (Chang et al., 2003); Candida infections (Beninati et al., 2000), 
and has also been applied to the delivery of cytokines in mammalian guts to relieve 
colitis (Steidler et al., 2000, Steidler, 2001). 
 
There are many symbionts that are able to express an array of molecules, which block 
pathogen development and have the potential to reduce pathogen transmission, but 
still there are many difficulties that need to be overcome. For example Chagas 
disease vector, Rhodnius prolixus, has been transformed by the symbiont 
Rhodococcus rhodnii to express a lethal peptide (cecropin A) to Trypanosoma cruzi 
parasite (Durvasula et al., 1997). Trypanosoma cruzi were reduced in the gut of R. 
prolixus without interfering with insect fitness (Durvasula et al., 1997). Furthermore, 
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functional antibodies have also been expressed without the use of antibiotic selection 
in the guts of R. prolixus (Durvasula et al., 1999) and Triatoma infestans (Durvasula 
et al., 1997, Durvasula et al., 2008).  
 
Paratransgenesis approaches, which control the spread of pathogens, are promising 
methods for controlling PD. As described earlier in section 1.7.2, many probable 
bacterial candidates have been suggested for this approach, including Alcaligenes 
xylosoxidans (Axd) and Pantoea agglomerans (Lacaval et al., 2009).  
 
In this project an anti-MopB scFv antibody expression cassette for Pantoea 
agglomerans, a promising paratransgenic bacterium (Pusey, 2002, Rio et al., 2004) 
was constructed using a constitutive promoter (lac promoter), pelB leader sequence, 
the selected functional anti-MopB scFv antibody (4XfMopB3) and a  
C-terminal 6xHis-tag (pARM4 plasmid) as described in section 2.18.4. This construct 
was successfully transformed into P. agglomerans. The pelB signal peptide from the 
pectate lyase-encoding gene of a related species, Erwinia carotovora (Sherald and 
Lei, 1991, Lei et al., 1987), was used due to its ability to lead the newly synthesised 
protein (scFv) to the periplasm by using the type II secretion pathway. The pelB 
signal peptide will be removed in the periplasm, from which the mature protein can 
leak out from the periplasm into the growth medium (Sandkvist, 2001).  
 
This expression cassette was expressed in both XL1-Blue E. coli and the  
P. agglomerans strains at 37 ºC. Western blot results for the overnight expression 
indicated that 4XfMopB3 scFv antibody was expressed in both strains but only  
E. coli was able to secrete the 4XfMopB3 scFv antibody. It is possible that the anti-
MopB scFv antibody was secreted by P. agglomerans but in low amounts 
undetectable by colorimetric detection in a Western blot and/or the secreted  
anti-MopB scFv antibody (4XfMopB3) was bound to the P. agglomerans surface 
proteins. These two hypotheses can be checked using a more sensitive Western blot 
detection system such as chemiluminescence detection and immunofluorescence 
assays (IFA). For immunofluorescence assays (IFA), a slide of P. agglomerans 
probing with anti-MopB 4XfMopB3 scFv antibody as primary antibody followed by 
secondary anti-polyHistidine-FITC antibody can be used.  
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To improve P. agglomerans scFv antibody expression and secretion, it is necessary to 
identify the optimal expression and secretion conditions. The anti-MopB scFv 
antibody was expressed in P. agglomerans and E. coli using the designed expression 
cassette at 37 ºC, while P. agglomerans is normally incubated at 30 ºC (Gavini et al., 
1989, Bisi and Lampe, 2011). It is important to reduce the temperature to 30 ºC and 
to optimise the codon usage to improve protein expression and secretion. 
 
In addition, the pelB signal peptide allows the passage of the protein (scFv) through 
the periplasm. Many problems such as periplasmic inclusion bodies, errors in folding 
or disulfide bond formation and degradation (Schlapschy et al., 2006, Kolaj et al., 
2009) may occur in the periplasm, which could explain the reasons for detection of 
the expressed scFv in the cell pellet but not in the culture media for P. agglomerans.   
 
4.8  Conclusion 	  
In this project the main goal was to generate recombinant scFv antibodies to be used 
to investigate the interaction of MopB with the plant and GWSS. Towards this goal, 
recombinant MopB has been produced and used with sera from five mice immunized 
with whole heat-killed X. fastidiosa in an ELISA. The ELISA results revealed the 
presence of antibodies against the recombinant MopB protein. The corresponding 
immune mouse spleens were used for 1st strand cDNA synthesis and these cDNA 
templates were used for PCR amplifying members of immunoglobulin variable 
region, 7 light chains and 10 heavy chains, families. The combinatorial libraries of 
single-chain fragment variable (scFv) antibodies were assembled in the VL-Link-VH 
orientation. These libraries were accessed for MopB specific recombinant scFv 
antibodies by in vitro ribosome display. Using the pAHAHis expression plasmid and 
Rosetta gami B(DE3) strain, selected anti-MopB scFv (4XfMopB3) was succefully 
expressed and purified from the E. coli cytoplasm and characterized by Western blot 
and ELISA,  and immunofluorescence assay binding to heat-killed X. fastidiosa.  
 
The results reveal that recombinant MopB proteins that are immunoreactive with sera 
from mice immunized with heat-killed X. fastidiosa had been produced. Such 
antibodies could have potential use in X. fastidiosa diagnostic applications. The 
recombinant anti-MopB could readily be engineered to agglutinate the bacteria and 
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introduced into the GWSS via paratransgenic organisms such as engineered Pantoea 
agglomerans.  In this study, P. agglomerans has been engineered with pARM4 (anti-
MopB scFv expression plasmid) to express and secrete the anti-MopB (4XfMopB3) 
scFv antibody. Despite this, P. agglomerans was not able to secrete the anti-MopB 
antibody but it was successfully expressed. 
 
Note: 
Parts of the results presented in this thesis have been published in Applied and 
Environmental Microbiology (AEM) (Appendix 2). 
AZIZI, A., ARORA, A., MARKIV, A., LAMPE, D. J., MILLER, T. A. & KANG, A. 
S. 2012. Ribosome Display of Combinatorial Antibody Libraries Derived 
from Mice Immunized with Heat-Killed Xylella fastidiosa and the Selection 
of MopB-Specific Single-Chain Antibodies. Applied and Environmental 
Microbiology, 78, 2638-2647. 
 
4.9  Future work 
 
Various approaches could be attempted to continue this work.  The results presented 
provide evidence that immunization with whole heat-killed X. fastidiosa clearly 
induces antibodies against surface exposed antigenic molecules exemplified by 
MopB. It is likely that the immune sera may also contain antibodies against other 
putative surface exposed molecules, some of which could have a role in virulence 
involving molecules intimately associated with attachment in either the GWSS or the 
grapevine xylem (Koide et al., 2006). One approach could focus on isolating more 
recombinant antibodies against MopB and other abundant surface exposed molecules 
on X. fastidiosa by using the in vitro anti- X. fastidiosa scFv libraries generated in this 
study, and the strategy for preparing recombinant putative membrane proteins 
provide a unique approach for discovering additional recombinant antibodies against 
surface components of X. fastidiosa. An alternative application for the antibody could 
be to engineer the selected antibodies for diagnostic applications by assembling the 
recombinant antibody molecules with in-built fluorophores (Markiv et al., 2011) for 
use in hand-held field-based microfluidic devices.  
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The genetically encoded molecules that target the surface of X. fastidiosa will 
facilitate the bacteria–vector interactions studies to develop intervention strategies 
such as paratransgenesis. Rhodococcus rhodnii bacterium was the first engineered 
symbiotic bacterium, which expressed and secreted cecropin A in Rhodnius prolixus, 
the Chagas disease vector (Durvasula et al., 1997), and subsequently to express a 
scFv antibody (Durvasula et al., 1999). Furthermore, a recombinant antibody against 
Plasmodium falciparum sporozoite surface protein (Chappel et al., 2004a, Chappel et 
al., 2004b) has been used to reduce P. falciparum sporozoite levels in Anopheles 
gambiae via an engineered entomopathogenic fungi (Fang et al., 2011). In the 
malaria study, the recombinant antibody targeted a surface accessible highly 
abundant target, the circumsporozoite protein, and was designed to agglutinate the 
parasite. Such an approach is independent of disrupting host cell specific interactions 
and may be a general strategy against targets that are present at high density on the 
pathogen surface.  
 
The next attempt will be to improve the expression and secretion of the anti-MopB 
scFv in P. agglomerans by identifying the optimal conditions, reducing the 
temperature to 30 °C and checking the codon usage. Then the newly engineered  
P. agglomerans, exhibiting the selected anti-MopB scFv generated will be tested at 
the University California Riverside in view of counteracting Pierce’s Disease. A 
possible avenue to take might be to infuse the genetically modified P. agglomerans 
into a known sample of grapevines and allow GWSS to feed on them. It would be 
most probable that the GWSS will easily pick up the modified P. agglomerans into 
its buccal cavity. Upon the subsequent feeding on infected (or even non-infected) 
grapevines, the genetically altered P. agglomerans might be able to displace or 
disrupt X. fastidiosa.  
 
Paratransgenesis (symbiotic control) offers a long-term solution to existent 
agricultural and infection disease problems. However, progress might be slow owing 
to the novelty of this particular application, the risk assessment, which is one of the 
most important concerns in using genetically modified symbiont, proving that the 
symbiont will not cause unexpected consequences, the regulatory process and 
approval requirements (Miller, 2011). Symbiotic control also demands for an 
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extensive background research on a particular symbiont and its niche should be 
exactly as that of the pathogen in question (both pathogen and symbiont should have 
evolved together over a defined period of time). It is important to remember the 
overall success of any paratransgenic strategy depends on the similar growth 
characteristics of the engineered strains and the wild type parent strain. 
 
Moreover, recombinant antibodies against MopB and other abundant surface exposed 
molecules on X. fastidiosa could be readily engineered to agglutinate the bacteria and 
introduced into the GWSS via paratransgenic organisms such as engineered Pantoea 
agglomerans, Metarhizium spp (Fang et al., 2011) or Beauvaria bassiana (Bukhari et 
al., 2011), or an avirulent strain of Xylella itself (Miller, 2011), providing new 
platforms to investigate controlling PD.  
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Appendix 1 	  
1.1  Bespoke and Bio-Rad protein markers size calibration graphs.  
 
Size calibration graph was plotted for both SDS-PAGE gel and Western blot results 
to show the correlation between two sets of protein marker. 
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1.2  Full length mature and truncated mopB sequence in pSANG10-3F vector. 
 
Showing: the NdeI, NotI and HindIIIsites, 6xHis-tag and Tri-Flag.	  	  
a)  Full length mature mopB in pSANG (1084 bp) 
 
atacatatggcccaggaattcgatgaccggtggtatctcgctggttccaccgggtttaac 
 I  H  M  A  Q  E  F  D  D  R  W  Y  L  A  G  S  T  G  F  N  
ttccaagataagcgtcgtcttactaacgatgctccttttttcgctcttggaattggtaag 
 F  Q  D  K  R  R  L  T  N  D  A  P  F  F  A  L  G  I  G  K  
ttcatcaatccagtttggtcgatcgacggcacactgaactatcagaacccgcagttcaaa 
 F  I  N  P  V  W  S  I  D  G  T  L  N  Y  Q  N  P  Q  F  K  
agaaacaaagatctaaactggagccaatatggcttctctgtcgattttcgtcgccatttc 
 R  N  K  D  L  N  W  S  Q  Y  G  F  S  V  D  F  R  R  H  F  
atccaggataaccgcggctggaatccttacttattgttaggagcggggtaccaacgttca 
 I  Q  D  N  R  G  W  N  P  Y  L  L  L  G  A  G  Y  Q  R  S  
gaggaggaatttgataacaccccaaacgtaaactcccctggcgaacgtaagaaaggcggc 
 E  E  E  F  D  N  T  P  N  V  N  S  P  G  E  R  K  K  G  G  
tttgctgctaaggtaggcgctggcttgcagacaacattcagaagccgtgtcgccgtccgt 
 F  A  A  K  V  G  A  G  L  Q  T  T  F  R  S  R  V  A  V  R  
gctgaagtagcttatcgtggtgaccatgataaggatagcgtgcgtcagccggtggctggt 
 A  E  V  A  Y  R  G  D  H  D  K  D  S  V  R  Q  P  V  A  G  
gttgcggcaccttccagcaagaaatggtttggtgataccttggcttcgattggtgtcgtg 
 V  A  A  P  S  S  K  K  W  F  G  D  T  L  A  S  I  G  V  V  
atcccatttggtccagccgcttcctcaccaacgccaccacctgctccgcctgctccaaca 
 I  P  F  G  P  A  A  S  S  P  T  P  P  P  A  P  P  A  P  T  
ccgccgccgccaccgcctgctccaagctgtgctgaattggatagcgatggagatggagtc 
 P  P  P  P  P  P  A  P  S  C  A  E  L  D  S  D  G  D  G  V  
aacgactgtgacgacaagtgcccgaactcacaaccaggccagacgatcggaccagatgga 
 N  D  C  D  D  K  C  P  N  S  Q  P  G  Q  T  I  G  P  D  G  
tgtccggtgccagtgtcgattgacttaaaaggcgtaaacttcgattttgacaagtctaag 
 C  P  V  P  V  S  I  D  L  K  G  V  N  F  D  F  D  K  S  K  
cttcgtcctgacgccgttgcggttcttaaggaggctaccgaaatcttgagacgctaccct 
 L  R  P  D  A  V  A  V  L  K  E  A  T  E  I  L  R  R  Y  P  
gacttgcacgtagaggtggctggccataccgattcgacaggtccggctgcttataacaaa 
 D  L  H  V  E  V  A  G  H  T  D  S  T  G  P  A  A  Y  N  K  
aagctatcggaacgtcgcgctaaagtcgtgtatgactacctgcgtaacaatggtatcgac 
 K  L  S  E  R  R  A  K  V  V  Y  D  Y  L  R  N  N  G  I  D  
gcatctcgcctgattgggccagtcggatatggggagacccatccaattgatacaaacaaa 
 A  S  R  L  I  G  P  V  G  Y  G  E  T  H  P  I  D  T  N  K  
accccagcaggtcgtgcgaagaaccgccgtactgagttgaacgttcagaatgcggccgca 
 T  P  A  G  R  A  K  N  R  R  T  E  L  N  V  Q  N  A  A  A  
ttatcacatcatcatcaccatcacaagctggactacaaagaccatgacggtgattataaa 
 L  S  H  H  H  H  H  H  K  L  D  Y  K  D  H  D  G  D  Y  K  
gatcatgacatcgattacaaggatgacgatgacaagtaataaaagctttaataagtcgag 
 D  H  D  I  D  Y  K  D  D  D  D  K  -  -  K  L  -  -  V  E  
caccac 




b)  Truncated  mopB in pSANG (564 bp) 
	  
atacatatggcccaggaattcgatgaccggtggtatctcgctggttccaccgggtttaac 
 I  H  M  A  Q  E  F  D  D  R  W  Y  L  A  G  S  T  G  F  N  
ttccaagataagcgtcgtcttactaacgatgctccttttttcgctcttggaattggtaag 
 F  Q  D  K  R  R  L  T  N  D  A  P  F  F  A  L  G  I  G  K  
ttcatcaatccagtttggtcgatcgacggcacactgaactatcagaacccgcagttcaaa 
 F  I  N  P  V  W  S  I  D  G  T  L  N  Y  Q  N  P  Q  F  K  
agaaacaaagatctaaactggagccaatatggcttctctgtcgattttcgtcgccatttc 
 R  N  K  D  L  N  W  S  Q  Y  G  F  S  V  D  F  R  R  H  F  
atccaggataaccgcggctggaatccttacttattgttaggagcggggtaccaacgttca 
 I  Q  D  N  R  G  W  N  P  Y  L  L  L  G  A  G  Y  Q  R  S  
gaggaggaatttgataacaccccaaacgtaaactcccctggcgaacgtaagaaaggcggc 
 E  E  E  F  D  N  T  P  N  V  N  S  P  G  E  R  K  K  G  G  
tttgctgctaaggtaggcgctggcttgcagacaacattcagaagccgtgtcgccgtccgt 
 F  A  A  K  V  G  A  G  L  Q  T  T  F  R  S  R  V  A  V  R  
gctgaagtagcttatcgtggtgaccatgataaggatagcgtgcgtcagccggtggctggt 
 A  E  V  A  Y  R  G  D  H  D  K  D  S  V  R  Q  P  V  A  G  
gttgcggcaccttccagcaagaaatggtttggtgataccttggcttcgattggtgtcgtg 
 V  A  A  P  S  S  K  K  W  F  G  D  T  L  A  S  I  G  V  V  
atcccatttggtgcggccgcatgctcacatcatcatcaccatcacaagctggactacaaa 
 I  P  F  G  A  A  A  C  S  H  H  H  H  H  H  K  L  D  Y  K  
gaccatgacggtgattataaagatcatgacatcgattacaaggatgacgatgacaagtaa 
 D  H  D  G  D  Y  K  D  H  D  I  D  Y  K  D  D  D  D  K  -  
Taaaagctttaataagtcgagcaccac 
 -  K  L  -  -  V  E  H  H 
 
 144	  
1.3  Recovered anti-MopB scFv’s (4XfMopB1-4) antibodies DNA sequences.  
 
Showing: the NcoI and NotI sites, variable light chain, linker and variable heavy 
chain. 
	  
a) 4XfMopB1 	  
The GenBank accession number for the 4XfMopB1 scFv is JQ606804. 
  
 
                                             accatggcagaaatt 
                                              T  M  A  E  I  
gtgctgacccagtttccaacatccctgtccgtggctacaggagaaaaagtcactatcaga 
 V  L  T  Q  F  P  T  S  L  S  V  A  T  G  E  K  V  T  I  R  
tgcataaccagcactgatattgatgatgatatgaactggtaccagcagaagccaggggaa 
 C  I  T  S  T  D  I  D  D  D  M  N  W  Y  Q  Q  K  P  G  E  
ccccctaagctccttatttcagaagccaatactcttcgtcctggagtcccatcccgattc 
 P  P  K  L  L  I  S  E  A  N  T  L  R  P  G  V  P  S  R  F  
tccagcagtggctatggtacggattttgtttttacaattgaaaacatgctctcagaagat 
 S  S  S  G  Y  G  T  D  F  V  F  T  I  E  N  M  L  S  E  D  
gttgcagattactactgtttgcaaagtgataacatgccttacacgctcggaggggggacc 
 V  A  D  Y  Y  C  L  Q  S  D  N  M  P  Y  T  L  G  G  G  T  
aaactggaggtgctacgtggtggtggtggttctggtggtggtggttctggcggcggcggc 
 K  L  E  V  L  R  G  G  G  G  S  G  G  G  G  S  G  G  G  G  
tccggtggtggtggttctcagctgaaggactcaggacctggcctggtggcgccctcacag 
 S  G  G  G  G  S  Q  L  K  D  S  G  P  G  L  V  A  P  S  Q  
agcctgtccatcacttgcactgtctctgggttttcattaaccagctatggtgtacactgg 
 S  L  S  I  T  C  T  V  S  G  F  S  L  T  S  Y  G  V  H  W  
gttcgccagcctccaggaaagggtctggagtggctgggagtaatatgggctggtggaagc 
 V  R  Q  P  P  G  K  G  L  E  W  L  G  V  I  W  A  G  G  S  
acaaattataattcggctctcatgtccagactgagcatcaacaaagacaactccaagagc 
 T  N  Y  N  S  A  L  M  S  R  L  S  I  N  K  D  N  S  K  S  
caagttttcttaaaaatgaacagtctgcaaagtgatgacacagccatgtactactgtgcc 
 Q  V  F  L  K  M  N  S  L  Q  S  D  D  T  A  M  Y  Y  C  A  
agagatcaggtctacggtagtagctactatgctatggactactggggtcaaggaacccct 
 R  D  Q  V  Y  G  S  S  Y  Y  A  M  D  Y  W  G  Q  G  T  P  
ctcaccgtttcctcggcggccgca 
 L  T  V  S  S  A  A  A  	  	  	  	  	  	  
NcoI    CCATGG          
 
NotI    GCGGCCGC     
 





b)  4XfMopB2 
 
 
                                 accatggcagacgtccagataatccag 
                                  T  M  A  D  V  Q  I  I  Q  
actccagcctccctatctgtatctgtgggagagactgtcaccatcacatgtcgagcaagt 
 T  P  A  S  L  S  V  S  V  G  E  T  V  T  I  T  C  R  A  S  
gagaatatttacagtaatttagcatggtatcagcagaaacagggaaaatctcctcagctc 
 E  N  I  Y  S  N  L  A  W  Y  Q  Q  K  Q  G  K  S  P  Q  L  
ctggtctatggtgcaacaaacttagcagatggtgtgccatcaaggttcagtggcagtgga 
 L  V  Y  G  A  T  N  L  A  D  G  V  P  S  R  F  S  G  S  G  
tctgggcaagattattctctaaccatcagcagcctggagtctgacgatacagcaacttat 
 S  G  Q  D  Y  S  L  T  I  S  S  L  E  S  D  D  T  A  T  Y  
tactgtctacagcatggtgagagccctctcacgttcggtgctgggaccaagctgacagtg 
 Y  C  L  Q  H  G  E  S  P  L  T  F  G  A  G  T  K  L  T  V  
ctacgtggtggtggtggttctggtggtggtggttcaggcggcggcggctccggtggtggt 
 L  R  G  G  G  G  S  G  G  G  G  S  G  G  G  G  S  G  G  G  
ggttctcagggggtggagtctgggggaggcttagtgaagcctggagggtccctgaaactc 
 G  S  Q  G  V  E  S  G  G  G  L  V  K  P  G  G  S  L  K  L  
tcctgtgcagcctctggattcagtttcagtaactatgacatgtcttgggttcgccagact 
 S  C  A  A  S  G  F  S  F  S  N  Y  D  M  S  W  V  R  Q  T  
ccagagaagaggctggagtgggtcgcgtccattagtagtggtattacctactatccagac 
 P  E  K  R  L  E  W  V  A  S  I  S  S  G  I  T  Y  Y  P  D  
agtgtgaagggccgattcaccatctccagagataatgccaggaacatcctgaacctgcaa 
 S  V  K  G  R  F  T  I  S  R  D  N  A  R  N  I  L  N  L  Q  
atgagcagtctgaggtctgaggacacggccatgtattactgtgcaagatattactacggt 
 M  S  S  L  R  S  E  D  T  A  M  Y  Y  C  A  R  Y  Y  Y  G  
actagcttctactggtacttcgatgtctggggcgcagggaccccgctcaccgtctctgcg 
 T  S  F  Y  W  Y  F  D  V  W  G  A  G  T  P  L  T  V  S  A  
gcggccgca 
 A  A  A  	  	  	  	  	  	  	  
NcoI    CCATGG          
 
NotI    GCGGCCGC     
 












c)  4XfMopB3 	  
The GenBank accession number for the 4XfMopB3 scFv is JQ606805. 
  
 
                                               accatggcagac 
                                                 T  M  A  D  
gtccagatgatccagactacagcctccctatctgcatctgtgggacaaactgtcaccacc 
 V  Q  M  I  Q  T  T  A  S  L  S  A  S  V  G  Q  T  V  T  T  
acatgtcgagcaagtgagaatattaacagttgtttagcatggtatcagcagaaacaggga 
 T  C  R  A  S  E  N  I  N  S  C  L  A  W  Y  Q  Q  K  Q  G  
aaatctcctcagctcctggtctataatgcaaaaaccttagcagaagatgtgccatcaagg 
 K  S  P  Q  L  L  V  Y  N  A  K  T  L  A  E  D  V  P  S  R  
ttcagtggcagtggatcaggcacacagttttctctgaagatcaacagcctgcagcctgaa 
 F  S  G  S  G  S  G  T  Q  F  S  L  K  I  N  S  L  Q  P  E  
gattttgggagttattactgtcaacatcattatggtactccgtggacgttcggtggaggc 
 D  F  G  S  Y  Y  C  Q  H  H  Y  G  T  P  W  T  F  G  G  G  
accaagctgaatctccaacgtggtggtggtggttctggtggtggtggttctggcggcggc 
 T  K  L  N  L  Q  R  G  G  G  G  S  G  G  G  G  S  G  G  G  
ggctccggtggtggtggttctcagatgcagcagcctggggcagaggttatgaagcctggg 
 G  S  G  G  G  G  S  Q  M  Q  Q  P  G  A  E  V  M  K  P  G  
gcctcagtcaagttgtcctgcacagcttctgacttcaacattaaagacacctttatgcac 
 A  S  V  K  L  S  C  T  A  S  D  F  N  I  K  D  T  F  M  H  
tgggtgaagcagaggcctgaacagggcctggagtggattggcaggattgatcctgcgatt 
 W  V  K  Q  R  P  E  Q  G  L  E  W  I  G  R  I  D  P  A  I  
ggtgaaactaaatatgacccgaagttccagggcaaggccactatagaagcagacacatcc 
 G  E  T  K  Y  D  P  K  F  Q  G  K  A  T  I  E  A  D  T  S  
tccaacacagcctacctgcagctcaccagcctgacatctgaggacactgccgtctattac 
 S  N  T  A  Y  L  Q  L  T  S  L  T  S  E  D  T  A  V  Y  Y  
tgtgcttttccccactactggggccaaggcacctcactcaccgtctcttcggcggccgca 







NcoI    CCATGG          
 
NotI    GCGGCCGC     
 







d)  4XfMopB4 
	  
                                          accatggtacaaaatctt 
                                           T  M  V  Q  N  L  
ctcacacagtctccagcaatcatgtctgcatctccaggggagaaggtcaccatgacctgc 
 L  T  Q  S  P  A  I  M  S  A  S  P  G  E  K  V  T  M  T  C  
agtgccagctcaagtgtaagttacatgcactggtaccagcagaagtcaggcacctccccc 
 S  A  S  S  S  V  S  Y  M  H  W  Y  Q  Q  K  S  G  T  S  P  
aaaagatggatttatgacacatccaaactggcttctggagtccccgctcgcttcagtggc 
 K  R  W  I  Y  D  T  S  K  L  A  S  G  V  P  A  R  F  S  G  
agtgggtctgggacctcttactctctcacaatcagccgaatggaggctgaagatgctgcc 
 S  G  S  G  T  S  Y  S  L  T  I  S  R  M  E  A  E  D  A  A  
acttattactgtcagcaaaggagtagttacccactcacgttcggtgctgggacaaagctg 
 T  Y  Y  C  Q  Q  R  S  S  Y  P  L  T  F  G  A  G  T  K  L  
gctatgaaacgtggtggtggtggttctggtggtggtggttctggcggcggcggctccggt 
 A  M  K  R  G  G  G  G  S  G  G  G  G  S  G  G  G  G  S  G  
ggtggtggttctcagcttcaggagtcgggacctgagctggtgtagcctggggcctcagtg 
 G  G  G  S  Q  L  Q  E  S  G  P  E  L  V  -  P  G  A  S  V  
aagatttcctgcaaagattctggctacacattcagtagtccttggataaactgggtgaag 
 K  I  S  C  K  D  S  G  Y  T  F  S  S  P  W  I  N  W  V  K  
cagaggcctggacagggtcttgagtggattggacggatttatcctggagatggaagaact 
 Q  R  P  G  Q  G  L  E  W  I  G  R  I  Y  P  G  D  G  R  T  
gactacaatggggacttcagggacaaggccacactgactgcagacaagtcctccagcaca 
 D  Y  N  G  D  F  R  D  K  A  T  L  T  A  D  K  S  S  S  T  
gcctacatgcagctcagtagcctgacatctgaggactctgcggtctattactgtgcaaga 
 A  Y  M  Q  L  S  S  L  T  S  E  D  S  A  V  Y  Y  C  A  R  
tcaagggatggtaactacggatattactatgctatggactactggggtcaaggaacccca 
 S  R  D  G  N  Y  G  Y  Y  Y  A  M  D  Y  W  G  Q  G  T  P  
ctcaccgtctcctcggcggccgca 







NcoI    CCATGG          
 
NotI    GCGGCCGC     
 
Linker  ggtggtggtggttctggtggtggtggttctggcggcggcggctccggtggtggtggttct 
 







1.4  4XfMopB3 scFv antibody DNA sequences in pAHAHis expression vector. 
 
Showing: the NcoI and NotI sites, variable light chain, linker, variable heavy chain, 
HA-tag and 6xHis-tag. 
 	  
            accatggcagacgtccagatgatccagactacagcctccctatctgca 
             T  M  A  D  V  Q  M  I  Q  T  T  A  S  L  S  A  
tctgtgggacaaactgtcaccaccacatgtcgagcaagtgagaatattaacagttgttta 
 S  V  G  Q  T  V  T  T  T  C  R  A  S  E  N  I  N  S  C  L  
gcatggtatcagcagaaacagggaaaatctcctcagctcctggtctataatgcaaaaacc 
 A  W  Y  Q  Q  K  Q  G  K  S  P  Q  L  L  V  Y  N  A  K  T  
ttagcagaagatgtgccatcaaggttcagtggcagtggatcaggcacacagttttctctg 
 L  A  E  D  V  P  S  R  F  S  G  S  G  S  G  T  Q  F  S  L  
aagatcaacagcctgcagcctgaagattttgggagttattactgtcaacatcattatggt 
 K  I  N  S  L  Q  P  E  D  F  G  S  Y  Y  C  Q  H  H  Y  G  
actccgtggacgttcggtggaggcaccaagctgaatctccaacgtggtggtggtggttct 
 T  P  W  T  F  G  G  G  T  K  L  N  L  Q  R  G  G  G  G  S  
ggtggtggtggttctggcggcggcggctccggtggtggtggttctcagatgcagcagcct 
 G  G  G  G  S  G  G  G  G  S  G  G  G  G  S  Q  M  Q  Q  P  
ggggcagaggttatgaagcctggggcctcagtcaagttgtcctgcacagcttctgacttc 
 G  A  E  V  M  K  P  G  A  S  V  K  L  S  C  T  A  S  D  F  
aacattaaagacacctttatgcactgggtgaagcagaggcctgaacagggcctggagtgg 
 N  I  K  D  T  F  M  H  W  V  K  Q  R  P  E  Q  G  L  E  W  
attggcaggattgatcctgcgattggtgaaactaaatatgacccgaagttccagggcaag 
 I  G  R  I  D  P  A  I  G  E  T  K  Y  D  P  K  F  Q  G  K  
gccactatagaagcagacacatcctccaacacagcctacctgcagctcaccagcctgaca 
 A  T  I  E  A  D  T  S  S  N  T  A  Y  L  Q  L  T  S  L  T  
tctgaggacactgccgtctattactgtgcttttccccactactggggccaaggcacctca 
 S  E  D  T  A  V  Y  Y  C  A  F  P  H  Y  W  G  Q  G  T  S  
ctcaccgtctcttcggcggccgcagatgtgccggattatgcgagcctcgagcaccaccac 
 L  T  V  S  S  A  A  A  D  V  P  D  Y  A  S  L  E  H  H  H  
caccaccactgagatccggctgctaacaaagcccgaaagagttatcctt 








1.5  4XfMopB3 scFv antibody DNA sequences in pARM4 plasmid 
 
Showing: the constitutive promoters, pelB sequence, NdeI, NcoI, NotI and HindIII 




                  catatgaaatacctgctgccgaccgctgctgctggtctgctg 
                   H  M  K  Y  L  L  P  T  A  A  A  G  L  L  
ctcctcgctgcccagccggccatggcagacgtccagatgatccagactacagcctcccta 
 L  L  A  A  Q  P  A  M  A  D  V  Q  M  I  Q  T  T  A  S  L  
tctgcatctgtgggacaaactgtcaccaccacatgtcgagcaagtgagaatattaacagt 
 S  A  S  V  G  Q  T  V  T  T  T  C  R  A  S  E  N  I  N  S  
tgtttagcatggtatcagcagaaacagggaaaatctcctcagctcctggtctataatgca 
 C  L  A  W  Y  Q  Q  K  Q  G  K  S  P  Q  L  L  V  Y  N  A  
aaaaccttagcagaagatgtgccatcaaggttcagtggcagtggatcaggcacacagttt 
 K  T  L  A  E  D  V  P  S  R  F  S  G  S  G  S  G  T  Q  F  
tctctgaagatcaacagcctgcagcctgaagattttgggagttattactgtcaacatcat 
 S  L  K  I  N  S  L  Q  P  E  D  F  G  S  Y  Y  C  Q  H  H  
tatggtactccgtggacgttcggtggaggcaccaagctgaatctccaacgtggtggtggt 
 Y  G  T  P  W  T  F  G  G  G  T  K  L  N  L  Q  R  G  G  G  
ggttctggtggtggtggttctggcggcggcggctccggtggtggtggttctcagatgcag 
 G  S  G  G  G  G  S  G  G  G  G  S  G  G  G  G  S  Q  M  Q  
cagcctggggcagaggttatgaagcctggggcctcagtcaagttgtcctgcacagcttct 
 Q  P  G  A  E  V  M  K  P  G  A  S  V  K  L  S  C  T  A  S  
gacttcaacattaaagacacctttatgcactgggtgaagcagaggcctgaacagggcctg 
 D  F  N  I  K  D  T  F  M  H  W  V  K  Q  R  P  E  Q  G  L  
gagtggattggcaggattgatcctgcgattggtgaaactaaatatgacccgaagttccag 
 E  W  I  G  R  I  D  P  A  I  G  E  T  K  Y  D  P  K  F  Q  
ggcaaggccactatagaagcagacacatcctccaacacagcctacctgcagctcaccagc 
 G  K  A  T  I  E  A  D  T  S  S  N  T  A  Y  L  Q  L  T  S  
ctgacatctgaggacactgccgtctattactgtgcttttccccactactggggccaaggc 
 L  T  S  E  D  T  A  V  Y  Y  C  A  F  P  H  Y  W  G  Q  G  
acctcactcaccgtctcttcggcggccgcatccgcacatcatcatcaccatcaccaccat 
 T  S  L  T  V  S  S  A  A  A  S  A  H  H  H  H  H  H  H  H  
cactaataaaagcttttaggggaggttccctttagtgagggttaattgcgcgcttggcgt 





2.1 Ribosome Display of Combinatorial Antibody Libraries Derived from Mice 
Immunized with Heat-Killed Xylella fastidiosa and the Selection of MopB-
Specific Single-Chain Antibodies. 
 
